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Abstract
Nanoparticle based drug delivery offers an advantage over free drug deliv-
ery as it allows the manufacturer to introduce various control mechanisms either
for targeted delivery or for the controlled release profile of the drug. Systems ca-
pable to encapsulate different active molecules, ranging from dyes to drugs, gained
a lot of attention in recent years. It was shown that it is possible to create a pro-
grammable device that can serve multiple functions ranging from enhanced imag-
ing techniques to cancer treatment along with extended drug delivery applications.
Therefore methods for fabrication and characterization of the devices that can be
used in the medical field is in high demand. Proposed is a device build around
propargyl acrylate nanoparticle along with a set of methods to fully characterize
the final nanocomposite composition. The release rate of the active molecules from
the proposed nanocomposite is compared to the composition of the device. The
ability to program the release rate and set a burst release temperature for the de-
vice is essential for future advances in drug delivery application.
Fo¨rster Resonance Energy Transfer (FRET) was used to investigate the changes
in the surface configuration. To do this, pair of dyes with good spectral overlap was
attached to the propargyl acrylate core. The donor dye was immobilized on the
surface of the core, while the acceptor dye was attached to the free end of the
poloxamer chain. This setup allowed the acceptor dye to have a certain degree of
ii
mobility. Based on the changes in the photo-luminescence spectra and applying
the FRET theory distance between the dyes was correlated to the temperature of
the environment. A possible mechanism of the surface configuration changes with
temperature was suggested based on the obtained results.
The ability of propargyl acrylate - poloxamer complex to capture, retain and
release when triggered small molecules is investigated. Often there is a need to
protect or deactivate an active molecule before it reaches its target organ or tissue
to prevent development of side-effects during treatment. Additionally, such a sys-
tem can be used for waste water treatment applications to remove toxic organic
contamination. The ability of the particles to trap and then release upon heating is
advantageous compared to the systems that are capable of only trapping because it
can be reused and serve the purpose of waste concentration to promote recycling
of otherwise wasted materials.
Proposed is a scheme of synthesis and characterization of the carrier based
on the propargyl acrylate nanoparticles coated with poloxamer copolymer. Carrier
stability is greatly enhanced, compared to similar systems found in the literature.
Advantage comes from the formation of a covalent bond between the core and the
shell, ensuring that no changes of the nano-carrier composition can happen during
its lifespan. This study shows the importance of the precise control over the graft-
ing density of the poloxamer on the surface of propargyl acrylate nanoparticle. The
ability to select various sizes of the nanoparticles and the selection of commercially
available poloxamer copolymers provide the possibility to fine tune properties of
the final carrier for the required task. The retention and release effectiveness was
correlated to the nano-carriers composition and was shown on the example of Rho-
damine B dye. The discovered principle of surface configuration changes during
FRET section of this study helped with determination of the release mechanism.
iii
Dedication
To my loving wife, Oksana Klep, whose unconditional love, support and en-
couragement provided me the strength and patience to pursue my dreams. To
my parents, Viktor and Svitlana Klep, whose support and kind advice helped me
through challenging times.
iv
Acknowledgments
The research included in this dissertation could not be completed without all
the help and support from many people. Foremost, I would like to express my thank
you to my advisor Dr. Stephen H. Foulger for mentoring me over the course of my
program, for teaching me how to use and more importantly how to trouble shoot
various analytical instruments, for possibility to play with and learn how to operate
an exceptional array of scientific tools. This work would not be possible without all
the support and guidance from my academic advisor. Besides my advisor, I would
like to thank the rest of my thesis committee members: Dr. Konstantin G. Kornev,
Dr. Igor A. Luzinov and Dr. O. Thompson Mefford for their time and attention to
the details that I have overlooked and for all the guidance through the challenging
parts of my thesis. It is because of their knowledge and suggestions that this work
was brought up to the high standard of PhD degree. Their experience in multitude
of materials science aspects made it possible to fill my thesis with crucial details
that made the work complete.
I would like to acknowledge the Department of Materials Science and En-
gineering, Department of Bioengineering and Center for Optical Materials Science
and Engineering Technologies, for allowing me to conduct this research and pro-
viding assistance. I am thankful to the faculty and staff of these departments, par-
ticularly, Dr. Gary Lickfield, Ms. Tonya Bledsoe, Ms. Sam Bradberry, Ms. Sheryl
v
Gonzales and Ms. Wendy Baldwin for all their help with document processing,
adaptation to new country and their time spend helping me to maintain my legal
status in the country and keeping me on track with my PhD program requirements
through constant reminders and follow-ups on all the document processing phases.
Also I want to say thank you to Ms. Kimberley Ivey for the countless hours
she spend showing me the fine art of analysis using non trivial approaches, for all
the support from her during hard times and for all her guidance through multiple
instrument repairs and upgrades.
I would like to thank all my colleagues over the past years who have been
with me during my journey to the PhD degree. I thank Dr. Yuriy Bandera for all
the synthesis help and guidance. Dr. Bogdan Zdyrko, Ms. Katie Burdette, Mr.
Tucker McFarlane, Dr. Ragini Jetty, Dr. Vladimyr Reukov, Ms. Olga Reukova, Mr.
Myhaylo Savchak for their advices, support and camaraderie through all my years
in Clemson.
I want to thank the Gregg-Graniteville Foundation and the National Science
Foundation (DMR-1507266) for financial support of this project. It would be im-
possible for me to come to United States and complete this research without the
financial support form these organization.
vi
Table of Contents
Title Page . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . i
Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ii
Dedication . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iv
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . v
List of Tables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix
List of Figures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . x
1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
2 Literature review . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.1 Temperature responsive polymers . . . . . . . . . . . . . . . . . . . . 8
2.2 Nanoparticles as a base for the drug delivery devices . . . . . . . . . 11
2.3 FRET as a mechanism of temperature sensor . . . . . . . . . . . . . . 13
2.4 Size determination . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
3 Micro-scale temperature sensor based on FRET effect . . . . . . . . . 20
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
3.2 Results and Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . 24
3.3 Conclusion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
3.4 Experimental methods . . . . . . . . . . . . . . . . . . . . . . . . . . 39
4 Control over poloxamer grafting density . . . . . . . . . . . . . . . . . 51
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
4.2 Results and Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . 58
4.3 Conclusion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
4.4 Experimental methods . . . . . . . . . . . . . . . . . . . . . . . . . . 83
5 Dependence of encapsulation and release efficiency of propargyl acry-
late poloxamer nanocomposite on the grafting density of poloxamer . 90
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
vii
5.2 Results and Discussions . . . . . . . . . . . . . . . . . . . . . . . . . . 94
5.3 Conclusion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
5.4 Experimental methods . . . . . . . . . . . . . . . . . . . . . . . . . . 107
6 Temperature triggered release of vancomycin . . . . . . . . . . . . . . 111
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
6.2 Results and Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . 114
6.3 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
6.4 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . 128
7 Concluding remarks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
7.1 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
7.2 Recommendation for future research . . . . . . . . . . . . . . . . . . 134
Appendices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152
A BET analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
B Poloxamer modification two end probability table . . . . . . . . . . . 154
C NMR data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155
D Copyright permission . . . . . . . . . . . . . . . . . . . . . . . . . . . 161
viii
List of Tables
2.1 Commercially available poloxamer and their respective basic proper-
ties. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
ix
List of Figures
1.1 Principal scheme of propargyl acrylate poloxamer nanocomposite mechanism of ac-
tion. Particles are synthesized, modified, loaded with drugs and then drug release
is triggered with temperature. Image created by Olga Reukova using Autodesk 3DS
Max software package. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
2.1 Illustration of the multifunctional imaging/therapeutic nanoparticle anatomy and
potential mechanisms of action at the cellular level. (A) A multifunctional nanopar-
ticle modified with targeting ligands extended from the nanoparticle surface with
polymeric extenders, imaging reporters (optical, radio, magnetic), and potential
therapeutic payloads (gene, radio, chemo). (B) Four possible modes of action for
various therapeutic agents; a) Specific nanoparticle binding to the cell surface re-
ceptors (i.e. enzymes/proteins) facilitate their internalization and/or inactivation,
b) controlled intercellular release of chemotherapeutics; c) release of gene thera-
peutic materials post endosomal escape and subsequent targeting of nucleus; and
d) intracellular decay of radioactive materials. Reprinted by permission from El-
siver publisher: [1] Advanced Drug Delivery Reviews Copyright 2010. . . . . . . 7
2.2 FRET Jablonski diagram with typical timescales. Absorption of the energy by the
donor causes one of the electrons to be promoted to a higher energy orbital. When
electron falls back to its lower energy state the energy is transferred to the acceptor
promoting one of the acceptor electrons to a higher energy orbital. When this
electron drops to the lower energy orbital the photon is emitted. Image created by
Alex M Mooney, licensed under the Creative Commons Attribution-Share Alike 3.0
Unported license . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
3.1 (A) Schematic representation of the built system, showing positioning of the dyes
on the surface of the nanoparticle. (B) Emission and absorption patterns of donor
dye (oxadiazole derivative - azOx) measured in tetrahydrofuran; excitation at 335
nm. (C) Emission and absorption patterns of acceptor dye (naphthalimide - Naph)
measured in tetrahydrofuran; excitation at 400 nm. . . . . . . . . . . . . . . 25
x
3.2 Photoluminescence of particles: (1) modified with oxadiazole dye (azOx) and
poloxamer (◦); modified with poloxamer terminated with naphthalimide dye (az-
PlurNaph) (—); (3) modified with both dyes azOx and azPlurNaph (•). All parti-
cles excited at 335 nm. Chromophores density for all samples is similar. Emission
for azOx modified nanoparticles at 400 nm was matched to the emission of dual
modified nanoparticles for better energy loss representation. azPlurNaph particle
density was matched to azOx particle density. Measurements taken at room tem-
perature. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
3.3 (A) Optical image of neat Pluronic-L64 (poloxamer/water) solution at room tem-
perature (left vial) and at 60 ◦C (right vial) (LCST is 58 ◦C). (B) Dependence of
micelles size and number of micelles formed by Pluronic-L64 in water with solution
temperature (measured through dynamic light scattering). . . . . . . . . . . . 27
3.4 Photoluminescence spectra of PA/azOx/azPlurNaph particles at various tempera-
tures. The donor dye is azOx with a peak emission ca. 400 nm, while the acceptor
dye is azPlurNaph with a peak emission ca. 550 nm. The LCST of the poloxamer, on
which the acceptor dye is attached at the end, is 58 ◦C. Particles dispersed in deion-
ized water and graphs are shifted for clarity. Excitation energy at a wavelength of
335 nm. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
3.5 FRET efficiency (◦) and calculated distance between the azOx and azPlurNaph
dyes (•) for the PA/azOx/azPlurNaph particles system (in water) presented in Fig-
ure 3.1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
3.6 Dependence of fluorescence emission on the absorbance for Anthracene, Naphthal-
imide and Oxadiazole. Based on these graphs, quantum yield dependence on the
temperature for Naphthalimide and Oxadiazole dyes was determined. . . . . . . 32
3.7 Proposed mechanism of the variation in photoluminescence response with temper-
ature of PA/azOx/azPlurNaph particles (cf. Figure 3.1A). At temperatures below
LCST, the PPO block forms a hydrophobic domain with loose packing which al-
lows the naphthalimide dye to sequester into its domain, but with a temperature
rise above LCST, the PPO domain packs more densely forcing the naphthalimide
dye from the domain, resulting in an increase of the distance between donor and
acceptor dyes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
3.8 Normalized integrated emission attributed to azOx (5) and azPlurNaph (4) dyes
in small molecule study performed with azOx, azPlurNaph, and the unmodified
poloxamer in deionized water. Sample was repeatedly heated to 65◦C (LCST of
poloxamer was 58◦C) and then allowed to cool down. For the donor dye (azOx),
the emission was integrated between 340 nm and 480 nm while for the acceptor
dye (azPlurNaph) the emission was integrated between 510 nm and 590 nm. The
sample was excited at a wavelength of 335 nm. . . . . . . . . . . . . . . . . 37
3.9 Scheme of AzOx dye synthesis. . . . . . . . . . . . . . . . . . . . . . . . . 42
3.10 Scheme of naphthalimide dye synthesis. . . . . . . . . . . . . . . . . . . . . 43
xi
4.1 Cartoon illustrating the influence of grafting density on the surface morphology.
(A). Nanoparticle with low grafting density of the shell, lots of open core surface,
limited temperature responsiveness. (B). Nanoparticle with optimal grafting den-
sity, all surface is covered, maximum temperature responsiveness. (C). Nanopar-
ticles with too high grafting density, shell chains restrict each others movement
ability decreasing temperature responsiveness. Cartoon is based on the theoreti-
cally calculated dimension of the core and poloxamer copolymer representing 0.15,
0.35 and 0.55 poloxamer chains per nm2 grafting density equivalents. Surface dec-
oration with poloxamer was done using Maya 2016 software package utilizing ran-
dom surface population with X-gen function of the software utilizing Mental Ray
package version 3.13.1.2. . . . . . . . . . . . . . . . . . . . . . . . . . . 54
4.2 Scheme of nanocomposite assembly. 1 - acryloyl chloride, 2 - propargyl alcohol,
3 - propargyl acrylate (PA) monomer (distilled under vacuum before polymeriza-
tion), 4 - Pluronic L-64, 5 - methyl sulfonyl mono-substituted poloxamer, 6 - azide
mono-substituted poloxamer, 7 - final assemble of PA nanoparticle decorated with
poloxamer chains. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
4.3 Poloxamer 1H NMR. A Methyl sulfonyl modified poloxamer. B Azide modified
poloxamer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
4.4 FTIR spectra of poloxamer (green line), PAn (black line) and mix of the two (red
line) showing three peaks of interest. Based on the ratio of the 1100, 1150 and
1728 cm−1 peaks calibration curves were created. . . . . . . . . . . . . . . . 63
4.5 Calibration curves build based on the 1100:1150 and 1100:1728 peak ratios for
poloxamer - PAn mix with mass ratio of the poloxamer ranging from 1% to 40%. . 65
4.6 Typical image observed during SEM imaging. To calculate average size and stan-
dard deviation 200 separate distinct cores were measured. . . . . . . . . . . . 67
4.7 Distribution of aggregates as observed with SEM, number average was counted. . 68
4.8 Number and intensity based average size distribution of the unmodified nanopar-
ticles before and after dialysis, and from the different fractions after size exclusion
chromatography. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
4.9 Amount of unmodified poloxamer left in the PAn poloxamer mixture after different
cleaning routines were attempted. Ligand exchange proved to be the fastest and
most efficient method for the removal of the unreacted poloxamer. . . . . . . . 73
4.10 Change in poloxamer grafting density of the PAPN after being exposed to 50 ◦C
temperature for one week. . . . . . . . . . . . . . . . . . . . . . . . . . . 76
4.11 Dependence of the achieved GD of the poloxamer on the time of the reaction. 5
times excess of azide modified poloxamer was added into the reaction and samples
were taken, cleaned and analyzed at 1, 3, 6, 24, 48, 96 and 168 hour. . . . . . . 77
4.12 Cartoon showing assumed conformation of the poloxamer covered nanoparticles
with calculated dimensions of the blocks. Ethylene oxide block is shown in green,
propylene oxide block is shown in red. . . . . . . . . . . . . . . . . . . . . 80
4.13 Dependence of poloxamer brush thickness on grafting density. . . . . . . . . . 82
xii
5.1 Scheme of the grab and release mechanism for the proposed system. A Device is
below LCST of the poloxamer. Poloxamer chains are in their expanded state. This
creates ample space for the dye to fit in. B Device is heated above LCST of the
poloxamer. Poloxamer chains are in their collapsed state. Free volume inside of
the shell is not sufficient enough to hold the dye any longer, the dye is released
into solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
5.2 Rate of Rhodamine B release from vesicles with different GDs below and above
LCST of the poloxamer used. Unmodified nanoparticles showed the best retention
and almost no release. Vesicles with poloxamer shell showed initial increase in
release capabilities with increase in GD, but after reaching GD of 0.35, poloxamer
chains per nm2 release effectiveness started to decrease until it almost completely
lost the temperature triggering capability. . . . . . . . . . . . . . . . . . . . 98
5.3 Schematic representation of the surface morphology based on the grafting density.
A. GD is low and a significant surface area is open, allowing the load to stick to
the surface rather than being trapped inside of the poloxamer pockets. B. GD
is optimal, all surface is covered with poloxamer chains, all load is encapsulated
inside of the poloxamer pockets. C. GD is too high, chain movement is restricted
by the neighboring chains, release rate is decreased compared to optimal GD. . . 100
5.4 Encapsulation effectiveness of vesicles with various GDs in the first 2 hours. Un-
modified nanoparticles were capable of holding close to 1 Rhodamine B molecule
per 3 nm2 of the surface, while modified nanoparticles were able to retain about
80% of this efficiency. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
5.5 Release rate, measured in grams of dye from gram of the cores, of the Rhodamine
B. Majority of the vesicles with poloxamer shell showed very similar release pat-
terns at room temperature which was relatively high at the beginning and leveled
out after 8 hours. The lowest GD sample showed a slower initial release but at the
same time it did not loose as much of the release rate with time and maintained
relatively linear release from the beginning. Unmodified particles worked mostly
as a grab and hold vesicle showing very limited release with time. . . . . . . . . 105
6.1 FTIR spectra of poloxamer (blue), PA particles (green) and mixture of the two
(red) showing good separation of the peaks for poloxamer (1100 cm−1) and PA
particles (1150 cm−1). Different grafting densities of poloxamer in PAPN can be
distinguished through the ratio of these two peaks. . . . . . . . . . . . . . . . 115
6.2 Left nanoparticle temperature is below LCST of the poloxamer, the shell is ex-
panded and can encapsulate vancomycin. Right image nanoparticle temperature is
above LCST of the poloxamer, the shell is collapsed, vancomycin is released from
the shell. Image created by Olga Reukova using 3DMax software package. Dimen-
sions of the coils on the cartoon where scaled to represent the theoretically calcu-
lated dimensions of particle and poloxamer blocks, vancomycin was not drawn to
the scale for clarity. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
xiii
6.3 Absorbance of standard Vancomycin solutions, from supernatant after modified
nanoparticles were removed from the suspension and from unmodified nanoparti-
cles with vancomycin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
6.4 Dependence of maximum absorbance for standard vancomycin solutions on the
concentration of vancomycin in solution. Line represents linear curve fit, dots
actual recorded data for known concentrations. . . . . . . . . . . . . . . . . 119
6.5 Number of colonies that has grown on petri dish after E. coli bacteria was exposed
to PA particles with vancomycin, PAPN, PAPN with vancomycin, pure vancomycin
and control in phosphate-buffered saline (PBS) solution. Top graph bacteria was
incubated at 18C◦C, bottom graph - at 36◦C. . . . . . . . . . . . . . . . . . . 121
6.6 Normalized number of the colonies that survived at 36 ◦C compared to 18 ◦C .
Control sample is the Escherichia coli bacteria that was not treated with anything
and was just diluted with PBS to match bacteria concentration of other samples.
The rest of the samples were normalized against the Control sample. . . . . . . 122
6.7 Number of the colonies that survived at 36 ◦Ccompared to 18 ◦C. Control sample
is the Staphylococcus aureus bacteria that was not treated with anything and was
just diluted with PBS to match bacteria concentration of other samples. ”S” indi-
cates statistically significant difference from the control sample, ”NS” indicates no
statistically significant difference from control according to ANOVA calculator. . . 125
1 Probability of one and two end modification with azide group for poloxamer as
described in Chapter 4, probability calculations are based on the loading ratio that
was used for the reaction, higher loading ratio would lead to a much higher prob-
ability of dual end modified poloxamer creating a high probability to crosslink
multiple particles together. . . . . . . . . . . . . . . . . . . . . . . . . . . 154
2 1HNMR spectra of Pluronic L64 as received. δ 1.11 (32) CH3 groups from PPO
block, δ 3.38 (32) CH groups in PPO block, δ 3.53 (32) CH2 groups from PPO
block, δ 3.64 (48) CH2 groups from both PEO blocks. . . . . . . . . . . . . . . 155
3 1HNMR spectra of Pluronic L64 as received. δ 1.07 (29) CH3 groups from PPO
block, δ 3.33 (29) CH groups in PPO block, δ 3.47 (29) CH2 groups from PPO
block, δ 3.57 (36) CH2 groups from both PEO blocks. . . . . . . . . . . . . . . 156
4 1HNMR spectra of Pluronic L64 as received. δ 1.11 (32) CH3 groups from PPO
block, δ 3.06 (1) CH3 group from MeSO2 group, δ 3.38 (32) CH groups in PPO
block, δ 3.52 (32) CH2 groups from PPO block, δ 3.62 (48) CH2 groups from both
PEO blocks. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
5 1HNMR spectra of Pluronic L64 as received. δ 1.06 (32) CH3 groups from PPO
block, δ 3.33 (32) CH groups in PPO block, δ 3.47 (32) CH2 groups from PPO
block, δ 3.57 (48) CH2 groups from both PEO blocks. . . . . . . . . . . . . . . 158
6 1HNMR spectra of Pluronic L64 as received. δ 1.13 (32) CH3 groups from PPO
block, δ 3.07 (1) CH3 group from MeSO2 group, δ 3.38 (32) CH groups in PPO
block, δ 3.54 (32) CH2 groups from PPO block, δ 3.63 (48) CH2 groups from both
PEO blocks. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
xiv
7 1HNMR spectra of Pluronic L64 as received. δ 1.11 (32) CH3 groups from PPO
block, δ 3.38 (32) CH groups in PPO block, δ 3.52 (32) CH2 groups from PPO
block, δ 3.62 (48) CH2 groups from both PEO blocks, δ 1.40, 1.70, 1.86, 3.21,
7,14, 7.65, 8.38-8.64 Naphthalimide signals . . . . . . . . . . . . . . . . . . 160
xv
Chapter 1
Introduction
Poloxamer block copolymer offers a unique set of properties that make it a
potent candidate for the responsive component in drug delivery applications. Tem-
perature responsive behavior combined with the ability of the poloxamer to en-
capsulate various organic molecules creates the possibility to design new devices
that will have superior capabilities as compared to modern ones. One of the draw
backs of the poloxamers is the fact that the micelles that they form are dynamic and
sensitive to a wide range of environmental factors ranging from concentration de-
pendence to solution ion strength. One of the possible solutions of this draw back is
to immobilize poloxamer chains on the surface of the nanoparticle. Propargyl acry-
late with its alkyne groups on the surface offers a versatile platform to build from.
Poloxamer chains can be modified to include azide groups through which a strong
and permanent bond between a propargyl acrylate nanoparticle and a poloxamer
can be created. Immobilization of the poloxamer on the surface solves the micelle’s
instability issue since there is no possibility for the poloxamer to change its position-
ing with regards to its neighboring chains, thus any structure that can be adopted
by the chains for a specific temperature condition will be independent of any con-
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centration factors. Additionally propargyl acrylate core can be modified with other
active moieties like dyes, for enhanced imaging applications; drugs, for extended
drug delivery; targeting ligands, for targeted drug delivery creating a multifunc-
tional carrier that can serve multiple functions at once.
A propargyl acrylate poloxamer nanocomposite (PAPN) production is simpler
from the chemistry point of view but require more attention from the researcher on
the characterization end of the device production when compared to other core
shell systems. Most of the classical nanocomposite characterization techniques fall
short when attempting to characterize polymer on polymer systems requiring some
modifications to the technique or even a complete redesign of the method to adapt
it for the proposed device. In this work a quick and reliable technique for PAPN
characterization was developed and tested. Fourier transform infrared spectroscopy
was used to determine the grafting density of the poloxamer chains on the propar-
gyl acrylate surface with sufficient resolution and excellent reproducibility of the
results. Through the use of the designed method differences between PAPNs with
regard to the amount of the poloxamer on the surface were determined. It was
found that control over grafting density of the poloxamer allows us to control how
much of the drug can be released from the device. The ability to change the rate of
drug release is essential when designing new drug delivery vesicles and offers the
possibility to utilize the same strategy for a multitude of therapeutic applications.
Basic cartoon of the PAPN assembly and principal of operation is shown on
Figure 1.1. First propargyl acrylate nanoparticles are assembled using emulsion
polymerization. The next step involves the precise decoration of the nanoparticle
with the exact amount of poloxamer chains to create PAPN. Then this nanocompos-
ite is ready to encapsulate drugs or dyes with the possibility to release encapsulated
molecules upon heating.
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Stock propargyl acrylate NP Decorated with poloxamer
Loaded with drugDrug released
Figure 1.1: Principal scheme of propargyl acrylate poloxamer nanocomposite mechanism of ac-
tion. Particles are synthesized, modified, loaded with drugs and then drug release is triggered with
temperature. Image created by Olga Reukova using Autodesk 3DS Max software package.
Overview
A multitasking vesicle based on the propargyl acrylate nanoparticle is de-
scribed and characterized in this work. Control over the poloxamer grafting den-
sity proved to be a useful tool to program the release rate of the active molecules
from the nanocomposite. FRET theory helped with the determination of the release
mechanism and allowed us to design a nanoscale temperature sensor.
The chapters of this thesis are structured as follows:
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Chapter 2 offers an introduction to drug delivery with current challenges
and state of the art techniques. A brief discussion about the importance of the
nanoparticles as a base for the drug delivery vesicles is also presented. Tempera-
ture responsive polymers and their applications for medical devices are discussed
with special focus on the poloxamer family of copolymers highlighting their ad-
vantages over the other temperature-responsive polymers. Common techniques of
the nanoparticle size determination and their limitations are also discussed. FRET
theory and equations used in this study are presented.
Chapter 3 describes the nanoscale temperature sensor build from the propar-
gyl acrylate, poloxamer, naphthalimide and oxadiazole derivatives. Control over the
positioning of the components allowed us to create a nanosized temperature sensor
that utilizes the temperature dependence of the poloxamer coil dimensions to con-
trol the distance between a pair of dyes and thus influences the photo-luminescence
properties of the device. Changes in the photo-luminescence are correlated to the
changes in the environment temperature, allowing contact-free temperature mea-
surement. Changes in the photo-luminescence were found to be reversible and in
good agreement with FRET theory. Based on the observed results and previous
knowledge about the immobilized copolymer behavior, a mechanism of response is
discussed.
Chapter 4 shows the details about the synthetic procedures used during the
preparation of the propargyl acrylate - poloxamer nanocomposite. We used FTIR
based methods to determine the final grafting density of the poloxamer on the
propargyl acrylate core. Equations to calculate the final grafting density are de-
rived and the method’s precision is verified. Developed methods allowed us to
characterize the kinetics of the Click reaction, optimize the cleaning protocols for
the removal of any unattached poloxamer, and helped with the evaluation of the
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stability of the vesicles at the elevated temperatures.
Chapter 5 focuses on the encapsulation and release profiles of the system
built and is characterized according to the methods described in Chapter 3. Rho-
damine B dye was used as a model drug to evaluate device efficiency and to com-
pare release rates of samples with various grafting densities. Knowledge about the
mechanism of the poloxamer conformation changes due to temperature were used
to describe the mechanism of the burst release and helped to explain why there is
a need to closely monitor the grafting density on the final device.
Chapter 6 demonstrates the possibility of real world applications to enhance
drug delivery. The vancomycin, an antibacterial drug, and Escherichia coli, as test
subjects, were used to test the efficiency of the proposed nanocomposite. Efficiency
of drug encapsulation and release was compared to the unmodified nanoparticles
and pure drugs. Modified nanoparticles were proved to be capable of both encap-
sulation and triggered release, thus showing a significant increase in bacteria death
rate above LCST of the poloxamer used.
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Chapter 2
Literature review
Drug delivery using encapsulation of the active components in the compos-
ite vesicles offers a range of advantages [1, 2, 3, 4, 5, 6]. Ranging from the simple
idea of an active molecule protection from the environment [7, 8] to creation of
complex multitasking devices capable of identifying, targeting and treating cancer
cells [9, 10, 11, 12]. Good examples of the multitasking nanoparticle idea were
proposed by Veiseh[1], as shown on Figure 2.1. The ability to modify the surface
of nanoparticles with various active components allows a researcher to program
the behavior of the final nanocomposite. Covering the surface with temperature re-
sponsive polymers allows us to use the temperature to trigger the property changes,
while causing the release of the active molecules or activating/deactivating dyes for
imaging purposes. Typically this activation is achieved through the ability of some
polymers to shrink the dimension of their coils, while expelling anything that was
trapped inside into the solution [13, 14]
Cancer is characterized by uncontrollable growth of the abnormal cells that
cause normal tissues to lose their functions and often leads to death of the patient if
not treated in time [15], so devices that can specifically find, expose, and/or influ-
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Figure 2.1: Illustration of the multifunctional imaging/therapeutic nanoparticle anatomy and
potential mechanisms of action at the cellular level. (A) A multifunctional nanoparticle modified
with targeting ligands extended from the nanoparticle surface with polymeric extenders, imaging
reporters (optical, radio, magnetic), and potential therapeutic payloads (gene, radio, chemo). (B)
Four possible modes of action for various therapeutic agents; a) Specific nanoparticle binding to the
cell surface receptors (i.e. enzymes/proteins) facilitate their internalization and/or inactivation, b)
controlled intercellular release of chemotherapeutics; c) release of gene therapeutic materials post
endosomal escape and subsequent targeting of nucleus; and d) intracellular decay of radioactive
materials. Reprinted by permission from Elsiver publisher: [1] Advanced Drug Delivery Reviews
Copyright 2010.
ence the cancer tissue in the body are of high demand. Nanoparticle - based imaging
and cancer treatment have gained significant attention in recent years [16, 17, 18]
but there is still a vast field for improvement since none of the proposed methods
are 100% effective or selective. Most chemotherapy drugs that are highly potent
against cancer will also impact healthy tissues, so ability to spot the cancer at early
stages means that it can be treated using smaller quantities of the drugs, decreasing
the side effects of the treatment. The cancer’s slightly higher temperature compared
to normal tissues can be used as a targeting mechanism to activate the system [19].
To use this window of opportunity a device should have a temperature responsive
component with the appropriate activation temperature, thus even in the absence
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of active targeting ligands only the devices that reached the cancer tissue would be
activated, thus minimizing the side effects from the treatment. To summarize, there
is a clear need in the device that can be programmed to multitask to achieve effec-
tive treatment of cancer, or for that matter most any cell disorders through precises
delivery of the active molecules to the inflammation site.
One of the routes considered is to encapsulate the active drugs in drug deliv-
ery vesicles [20, 3] that have a temperature activated shell, and the best way to do
this is through the use of temperature responsive polymers. Because of this there
has been a constant increase in the interest in the responsive polymer field over
the last few decades. This interest has arisen due to the ability of temperature re-
sponsive polymers to undergo conformational changes as a function of the external
temperature.
2.1 Temperature responsive polymers
Temperature responsive polymers exhibit changes in their conformation in
an aqueous solutions at or around a specific temperature [21]. These changes are
characterized by either a lower critical solution temperature (LCST) or an upper
critical solution temperature (UCST); some polymers can have a combination of
both [22]. These temperatures represent the borders above or below which the
polymer and medium are no longer miscible. The width of the temperature range
where this change is happening is highly dependent on the purity of the polymer
and its polydispersity [23]. The lower the polydispersity of the polymer is, the
narrower the temperature range of the response; therefore, the release of the active
molecules will be happening over the narrower temperature range while decreasing
the requirement for the difference in the temperature for the activation of the device
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created from these polymers.
The most common types of such polymers are N-alkylacrylamides (Poly(N-
isopropyl acrylamide) - PNIPAM, most common), vinyl ethers, alkylaminoalkyl-
(meth)-acrylates, vinylcaprolactam, and poloxamer copolymers [24]. Two of the
most used types are PNIPAM and alkylene oxide polymers or poloxamers [25]. The
main disadvantage of the PNIPAM is its relatively hard synthesis, and the even
more difficult modification of the end groups [26, 27]. It is hard to change the
LCST temperature of PNIPAM, as it does not have any dependence on the molecular
weight of the polymer [28]. The only way to change PNIPAM LCST is to copoly-
merize NIPAM with other monomers, which further complicates the synthesis [29].
Poloxamer polymers are much easier to synthesize at various sizes and copolymer
compositions [30]; the end groups are hydroxyl groups, so they can be changed
into other functional groups by using conventional methods. And more importantly
poloxamers LCST temperature is dependent on the size and the composition of the
copolymer, which is easy to control during synthesis [31]; thus, the LCST can be
easily tuned to be in the desired temperature region. Poloxamer copolymers are
commercially available with LCST ranging from 15 ◦C up to 100 ◦C and are pro-
duced in millions of tons per year. The list of some of the commercially available
poloxamers are shown in Table 2.1 along with their main properties.
Besides being readily available in a wide range of LCST temperatures polox-
amer family of copolymers offers a set of important properties that are desired in
drug delivery applications. The first advantage comes from the structure of the
copolymer: the outer ethylene oxide blocks act as a protective layer between the
vesicle and the human body environment[32]. Immune system function is to de-
stroy any foreign object that it can find inside of the human body. The particulates
that are covered with ethylene oxide are processed by the immune system as the na-
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Name Mn LCST %PO %EO Name Mn LCST %PO %EO
L122 5000 19 80 20 P75 4200 82 50 50
L72 2750 25 80 20 P85 4600 85 50 50
F62 2500 32 80 20 P103 4950 86 70 30
L63 2650 34 70 30 P123 5750 90 70 30
L42 1550 37 80 20 P105 6500 91 50 50
L43 1850 42 70 30 F38 4700 100 20 80
L64 2950 58 60 40 F68 8350 100 20 80
L44 2200 65 60 40 F77 6700 100 30 70
L35 1900 73 50 50 F87 7700 100 30 70
P84 4200 74 60 40 F88 10800 100 20 80
P104 5850 81 60 40 F98 13000 100 20 80
P65 3600 82 50 50 F108 14000 100 20 20
Table 2.1: Commercially available poloxamer and their respective basic properties.
tive components and as such are not destroyed by the immune system [33]. Ability
of a device to remain intact while circulating through the human body environment
is crucial, as it allows enough time for the device to spread through the body, find
its target organ, and complete the designed mission.
A second advantage of the poloxamers comes from their ability to influence
the cell wall penetration characteristics while allowing the drugs to penetrate inside
of the cell [34]. Cell wall permeability is often responsible for drug resistance and
the ability to increase this permeability means that less drugs can be used to achieve
the same therapeutic effect. This, in turn, leads to a decrease in the side effect
probabilities.
A third and final advantage of the poloxamers is the availability of the rel-
atively active hydroxyl groups on the copolymer ends. Plenty of chemistry has
been developed that allows a researcher to substitute the hydroxyl groups with
other functional groups that are needed during the final assembly of the drug deliv-
ery device, all while allowing the creation of a stable and well-established surface
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chemistry.
Poloxamers can form micelles under certain conditions [30], but these mi-
celles are susceptible to self destruction if the conditions change. A common solu-
tion to this problem is the immobilization of the polymer on the surface of the stable
nanoparticle. The best way to successfully immobilize the polymer on the surface
is to chemically bind it. The possibility to replace one of the hydroxyl groups on
the poloxamer chain with the azide group allows us to use Azide-alkyne Huisgen
cycloaddition reaction to permanently attach the copolymer to the surface under
mild conditions, while reaching high yields during this process [35].
2.2 Nanoparticles as a base for the drug delivery de-
vices
Nanoparticles appear in a growing number of the research articles when it
comes to drug delivery field. This is happening because through the use of the
nanoparticles it is possible to achieve multiple goals at once and, thus, to solve mul-
tiple problems associated with drug delivery. The first advantage of the nanoparticle
as a base for drug delivery devices comes from the possibility to control the size of
the final device [36]. This allows for a design vesicle with required penetration
capabilities and utilizes the differences of the cell/tissue penetration properties for
the targeted drug delivery applications [37, 38, 39].
The second advantage of the nanoparticles involves the ability to control the
surface chemistry and, as a result, the morphology. Propargyl acrylate nanoparti-
cles are one of the examples of a bio-compatible carrier with easy-to-control surface
chemistry [40]. Through the strategic positioning of the active components on the
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surface it is possible to design a multitasking device [40, 41, 42]. Various small
molecule targeting ligands can be attached to enhance the targeting capabilities of
the device while enhancing the treatment efficiency and decreasing the side effects
from the treatment. One such example is the gefitinib ligand [43]. Gefitinb specif-
ically binds to the epidermal growth factor receptor, also known as EGFR, on the
surface of the cells. Expression of the EGFR on the cancer cells is typically two to
three orders of magnitude higher than on the healthy cells [44], EGFR is thought
to be responsible for the increased cancer cell viability and the ability of cancer
cells to grow much faster than normal cells. The device that can recognize and
specifically bind to the EGFR will lead to a two to three orders of magnitude higher
device concentration near the cancer cells as compared to the healthy cells, and
this fact combined with a triggered release can create a higher concentration of the
drug around the cancer cells, all while maintaining low drug concentration near the
healthy cells.
The possibility to build a specific structure on the surface of the nanoparticle
allows us to create sensors that can detect changes of the environment on a micro
scale without the need for wires or other invasive measuring devices [45, 46]. Most
of the time the analysis of the environmental change is correlated to the changes in
the luminescence of the nanoparticle [47]. Several approaches are used to create
a device that can change the photo-luminescence profile when exposed to different
conditions. Some of the approaches rely on the turn on or turn off of the dye when
the dye is located in the vicinity of the core [48], while the others use the energy
transfer dependence on the distance, also known as Fo¨rster or fluorescence reso-
nance energy transfer (FRET)[49, 50]. When two dyes are located close enough
and their spectral properties overlap, part of the energy from the donor dye can be
transferred to the acceptor dye and the amount of the energy transferred is propor-
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tional to the distance between the dyes and can be found using FRET theory [51].
Use of the nanoparticles as a base for the medical device fabrication is ad-
vantageous in many aspects. It allows for a creation of programmable vesicles that
can encapsulate, protect, deliver and then release the active molecules into the site
of interest. Additionally when the dyes are strategically positioned on the surface,
and when the distance between these dyes is dependent on the environment pa-
rameters, a sensor to monitor these parameters can be created. So acquiring new
knowledge about the synthesis and the characterization methods for the nanocom-
posites is essential for the future advances in the nanoparticle-based drug delivery
systems and their imaging applications.
2.3 FRET as a mechanism of temperature sensor
Fo¨rster or fluorescence resonance energy transfer (FRET) is a process of en-
ergy transfer between two light-sensitive molecules called chromophores. A donor
dye absorbs the photon, which promotes the electron from its highest occupied
molecular orbital (HOMO) to become excited and to jump to a higher energy level.
Then the electron loses part of this excess energy through one of the possible mech-
anisms: photon emission, heat, or transfer of energy through dipole-dipole coupling
to the acceptor molecule, exciting acceptor electron from HOMO to a higher energy
level. Then the electron on the acceptor relaxes back to its ground state through
one of the above mechanisms, and if it emits the photon, that can be measured,
a significant red shift of the emission observed [52]. This principle, including the
typical time scales for each of the proces’s, is shown on Figure 2.2.
To achieve any significant FRET, the pair of dyes has to satisfy all of the FRET
criteria: including significant spectral overlap of the donor emission spectrum with
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Figure 2.2: FRET Jablonski diagram with typical timescales. Absorption of the energy by the
donor causes one of the electrons to be promoted to a higher energy orbital. When electron falls
back to its lower energy state the energy is transferred to the acceptor promoting one of the acceptor
electrons to a higher energy orbital. When this electron drops to the lower energy orbital the photon
is emitted. Image created by Alex M Mooney, licensed under the Creative Commons Attribution-
Share Alike 3.0 Unported license
the absorption spectrum of the acceptor; quantum yield of the donor has to be
high; donor and acceptor transition dipoles must be in the same orientation plane;
and the distance between the donor and the acceptor has to be less than twice the
Fo¨rster distance. Fo¨rster distance is a distance at which FRET is 50% efficient often
referred to as a characteristic distance, and is typically ranges from 2 to 6 nm.
FRET is characterized using the rate of energy transfer kτ, and the rate of the
energy transfer can be estimated from the following equation:
kτ =
1
τD
(
R0
r
)6
where kτ is the rate of the energy transfer from the donor to the acceptor;
τD is the decay time of the donor in the absence of the acceptor; R0 is the Fo¨rster
distance; r is the real distance between the donor and the acceptor at a given condi-
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tion. As the above equation demonstrates, FRET is highly dependent on the distance
between dyes - to the sixth power. Even small changes in the distance between the
dyes can yield big differences in FRET. This is why controlling the distance between
the dyes is so important and can be used as a tool to modify the emission spectra
of the system. Energy transfer requires for the donor and the acceptor to be within
a characteristic distance and to have suitable spectral overlap. The value of R0 can
be reliably predicted from the spectral characteristics of the donor and the acceptor
using following equation:
R0 = 0.211(κ2n−4QDJ(λ))
1
6
where QD is the quantum yield of the donor; κ2 is the factor describing the
relative orientation in space of the transition dipoles of the donor and the accep-
tor and is usually assumed to be equal to 23 , which is appropriate for the dynamic
random averaging of the donor and acceptor orientations; n is the refractive index
of the medium; the overlap integral J(λ) represents the extent of the spectral over-
lap between the emission of the donor and the absorption of the acceptor at the
wavelength range λ to λ+δλ and can be estimated from the following equation:
J(λ) =
∫
FD(λ)εA(λ)λ4dλ
where FD(λ) is the corrected fluorescence intensity of the donor in the wave-
length range λ to λ+ δλ, with the total intensity normalized to unity; εA(λ) is the
molar extinction coefficient of the acceptor at λ.
Knowledge of the rate of energy transfer allows us to estimate the efficiency
of the energy transfer E. E is the fraction of the photons absorbed by the donor that
are transmitted to the acceptor. E can be found from the ratio of the total decay
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rate of the donor to the total transfer rate between the dyes through equation:
E =
kτ
τ−1D + kτ
Substituting the kτ in the above equation with kτ equation the efficiency of
the energy transfer can be found through the lifetime differences of the donor dye
in the presence and absence of the acceptor using following equation:
E = 1− τDA
τD
Calculated this way values for the efficiency of the energy transfer allow to
estimate the distance between the dyes using the following equation:
r = (
R60
E
−R60)
1
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Knowing the surface chemistry and positioning of the dyes on the surface of
the nanocomposite allows us to use the distance between the dyes as an indication
of the surface morphology changes and, as such, to make a prediction of the device’s
behavior at a given condition.
2.4 Size determination
Precise surface chemistry characterization, specifically the grafting density
determination, depends on the ability to measure the sizes of the cores accurately.
Dynamic light scattering (DLS) and Scanning Electron microscopy (SEM) are among
the most common techniques used to determine the size of spherical vesicles[53,
54, 55]. DLS gives an intensity-weighted mean value of the hydrodynamic radius
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of the vesicle and is often the first tool of choice in the nanoparticle characteriza-
tion. To convert hydrodynamic radius value to a number or volume-weighted mean
value that can be used in the grafting density determination one needs to know
the complex refractive index of the material. This requirement is the main reason
why often obtaining real information about the dimensions of the vesicle is im-
possible. Though still the DLS allows us to reliably compare the different samples
among themselves, as long as the material is the same and the only difference is
in the size. SEM, on the other hand, provides the information about the size and
the shape of the dried vesicles, so if the vesicle swells in the environment SEM will
show a smaller size compared to real dimensions in solution[56], this is why DLS
is a more preferred way of the nanoparticle size determination in most cases. Com-
bination of the two techniques allows us to make a much more accurate prediction
about the real solution size of the studied object as compared to data from just one
technique.
In the DLS measurements particle size is determined through the monitor-
ing of the rate of the particle’s diffusion in the fluid. This rate depends on the fluid
temperature, viscosity of the solvent and the nanoparticle size. The first two com-
ponents are easy to control and can be precisely measured, and this allows for the
determination of the third component - particle size.
Principle of the DLS instrument operations are as follows: instrument illumi-
nates the particles with a laser and measures the scattered light with a photomulti-
plier tube (PMT). Intensity of the light detected by PMT depends on the pattern of
the particles in the laser beam. As particles move through the laser beam, intensity
of the scattered light changes and by monitoring the speed of the intensity change it
becomes possible to make a decision about the particle size. Bigger particles move
slower and, thus, the intensity changes are slower when compared to the smaller
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nanoparticles.
In order to obtain information about the particle size from the intensity
changes, the instrument uses a mathematical transformation which is called auto-
correlation function. Basic algorithms behind the auto-correlation function are the
comparison of a scattering intensity at time t to intensity at time t+τ . If the corre-
lation of the two intensities is high, the intensity has not changed much, this means
that the particles have not changed their relative position much, and this is the di-
rect indication of a big size of the particles, big things move slower than smaller
ones. Instrument monitors this auto-correlation over a defined period of time and
for various values of τ , then compares the obtained values to build a decay time
graph. Time differential when auto-correlation curve changes from 1 (high corre-
lation) to 0 (no correlation) is indicative of the particle size and when information
about particle’s refractive index is available the hydrodynamic radius (Rg) of the
particles can be calculated[57, 58]. Precise determination of a complex refractive
index (RI) of a nanoparticle is required to obtain a real value of Rg, and because
often it is impossible to get an accurate measurement of RI, size of the nanoparticle
determined using DLS is only an approximation, and thus there is a need for the
additional size measurements to confirm the real size of the nanoparticle.
Often during synthesis the same processes that hold nanoparticles intact can
lead to the attachment of two or more nanoparticles together. Alternatively, parti-
cles can stick together during storage after they have been synthesized. This com-
bination of nanoparticles leads to a formation of aggregates and leads to increased
polydispersity readings during DLS measurements. To determine the presence of
the aggregates, nanoparticles can be separated according to their size using column
chromatography. Depending on the size of the nanoparticle, the time required to
pass through the column will be different thus making it possible to separate the
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different fractions and analyze the average size of the nanoparticles in each fraction
separately. If the sample has a mix of the single nanoparticles and aggregates after
column chromatography these sets will be isolated. Running DLS measurements on
each of the fractions allows us to determine the extent of aggregation and thus to
make a better prediction about the final composition of the sample.
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Chapter 3
Micro-scale temperature sensor
based on FRET effect
An effective strategy to control the Fo¨rster resonance energy transfer (FRET)
of a donor/acceptor emitter pair that were attached to a 60 nm poly(propargyl acry-
late)(PA) nanoparticle using temperature variations was developed. The size de-
pendent properties of a poly-(ethylene oxide)-poly-(propylene oxide)-poly-(ethylene
oxide) (PEO-PPO-PEO) block copolymer (poloxamer) was exploited to vary the
spatial separation of the emitters and vary the FRET efficiency. Specifically, a 2%
change in FRET efficiency between the donor/acceptor pair was achieved per 1 ◦C
change in temperature from 49 ◦C to 60 ◦C when using a poloxamer of 2950 g/mole
molecular weight, with sections of PPO consisting of 32 repeat units, PEO sections
consisting of 12 repeat units and a lower critical solution temperature (LCST) of
58 ◦C. The methodology presented in this effort is easily extended to other temper-
ature regimes through a judicious choice in poloxamer and corresponding LCST.
.
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3.1 Introduction
A particularly interesting and well-known optical emitter-emitter interac-
tion is Fo¨rster resonance energy transfer (FRET) and has been widely utilized as
a tool for signaling[59, 60] and measuring[61] molecular associations in biomed-
ical and clinical applications, although many applications exploit FRET, including,
photovoltaics[62], lighting & displays[63], and sensors[49]. FRET is a near-field
nonradiative energy transfer between pairs of dipoles where the excitation energy
is transferred from one emitter, referred to as the “donor”, to a second emitter,
referred to as the “acceptor”[64, 65].
Extensive research has been done on utilizing organic dyes in FRET assays
with much success[50]. These small molecule systems have the advantage of sim-
ple preparation and low cost, resulting in a large variety of these dyes being com-
mercially available for diverse applications. Nonetheless, these systems can suffer
from poor photo-bleaching resistance[66], short fluorescence life time, low fluo-
rescence quantum yield[67], non-specific quenching[68, 69], low chemical sta-
bility and intracellular toxicity. In addition, small molecule dyes often will bind
to proteins[70], which leads to aggregation and subsequent elimination from the
body. In response to the limitations, fluorescent proteins are being used increas-
ingly in FRET systems. In these systems, a fluorophore is genetically appended onto
the gene coding for a protein of interest so that a fluorophore and protein can then
be co-expressed intracellularly and, when imaged, reveal the location and relative
expression level[71, 72]. Since the initial development of green fluorescent protein
(GFP), efforts on extending the color regime of the protein have resulted in a range
of available colors for the fluorescent proteins[73]. Though these systems continue
to develop and offer exciting new applications, there are challenges to coupling
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them to targeting, diagnostic, and therapeutic payloads.
One approach to remedy these shortcomings is the inclusion of the chro-
mophores on the surface of colloidal particles[74, 75, 76]. This attachment of
the dye to a particle results in an extension of circulation half-life and enhanced
in vivo stability relative to the free fluoroprobe[75]. The surface attachment of
the dyes allows them to participate in advantageous host/guest assemblies that
can alter their emission and FRET efficiency. This response can be utilized as a
biologically-based sensor or switch due to the noticeable variations in the emission
spectra when they form supra-molecular host/guest assemblies or complex with bio-
macromolecules[77, 78, 79]. The environmental sensitivity in the emission prop-
erties of the chromophores can also be exploited to assist in refining the proposed
parameters that govern molecular recognition[80, 81, 82]. Photo-stable fluores-
cence nanoparticles which can be good candidates as donors in FRET that have re-
ceived recent attention include semiconductor quantum dots (QDs)[83], graphene
quantum dots (GQDs)[84, 85] and upconversion nanoparticles (UCNPs)[86, 87].
In the current effort, colloidal particles are developed that exhibit a sig-
nificant change in FRET efficiency within a specified temperature regime. The
methodology utilized is relatively general, and the system can be easily extended
to operate in a wide range of temperature zones. Specifically, sub-100 nm parti-
cles are surface modified with two dyes that form a FRET pair. One of the dyes
is attached to the particle through a copolymer that exhibits significant changes
in its dimensions with temperature variations, and this temperature sensitivity is
exploited to alter the spatial proximity of the donor and acceptor dyes, which al-
ters the dyes’ FRET efficiency and thus reporting on the temperature alteration.
The class of polymer used is a poly(ethylene glycol)-block-poly(propylene glycol)-
block-poly(ethylene glycol) (PEO-PPO-PEO) difunctional block copolymer often re-
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ferred to as a “poloxamer”. Poloxamer copolymers can change their excluded vol-
ume (“size”) depending on the surrounding temperature and can form hydropho-
bic pockets that attract hydrophobic molecules, especially aromatic molecules, and
stabilize them in aqueous environments[88, 31, 89]. This property is utilized in
medical applications to promote the activity of hydrophobic dyes and drugs, that
are otherwise ineffective in the aqueous environment of live cells[90, 91]. Another
advantage of using poloxamers comes from their tri-block copolymer structure. The
outer blocks are composed of ethylene oxide (EO) which is known to form vesicles
that can engulf a payload rendering it invisible to the reticulo-endothelial system
and macrophages, and therefore significantly increasing the lifetime of the payload
in the body[92, 93, 94, 95]. In addition, poloxamer surfactants have been reported
to increase the sensitization of tumors with respect to various anticancer agents
[96, 97, 98], making anticancer drugs more effective.
Unfortunately, free poloxamers cannot create stable polymersomes below
critical micellization concentration or temperature and they require additives to
make stable vesicles[99] or the attachment to a nanoparticle to create a stable
platform[93, 95]. Free floating poloxamers are very sensitive to the load that
they carry and to the surrounding conditions[31], increasing the likelihood that the
formed micelles will be damaged, which results in the loss of content effectively ren-
dering them useless or, worse, triggering an unwanted side effects, such as general
system toxicity. Immobilization of the poloxamer on the surface of nanoparticles
eliminates these issues allowing the system to maintain its functionality[90]. Based
on these characteristics, a poloxamer was chosen as the responsive component of
the proposed colloidal device. In addition, the use of a particle as the platform on
which various other “loads” can be attached[100, 41] is advantageous as it allows
for further modifications with targeting ligands and therapeutic drugs[101, 102].
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3.2 Results and Discussion
Figure 3.1A presents the system utilized in this study, which was composed
of a propargyl acrylate (PA) nanoparticle, which had two complementary FRET
dyes attached to its surface, with the acceptor dye being attached to the parti-
cle through a modified poloxamer. The donor dye was an oxadiazole derivative
(azOx, cf. Figure 3.1B) that was attached directly to the surface of the PA nanopar-
ticle through an azide-alkyne Huisgen cycloaddition resulting in a 1,2,3-triazole
(“Click” transformation)[100], while the acceptor dye, a naphthalimide derivative
(azPlurNaph, cf. Figure 3.1C), was attached to the same nanoparticle through a
poloxamer chain. The poloxamer (Pluronic-L64) was a poly(ethylene glycol)-block-
poly(propylene glycol)-block-poly(ethylene glycol) (PEO-PPO-PEO) difunctional block
copolymer that initially terminated in primary hydroxyl groups but was modified so
that one end contained a naphthalimide dye and the other an azide group so that it
could also be “clicked” to the particle (cf. Experimental methods). The unmodified
PEO-PPO-PEO triblock copolymer had a molecular weight of 2950 g/mole, with the
sections of PPO consisting of 32 repeat units, while the PEO section consisted of 12
repeat units. The poloxamer exhibits a lower critical solution temperature (LCST)
of 58 ◦C.
Free poloxamers typically form polymersomes of several hundred nanome-
ters [31]; however, immobilizing them on nanoparticles of a fixed size limits the
maximum size of the system to the sum of the size of the nanoparticle used plus
twice the length of the fully extended poloxamer chain. Vesicle size is very impor-
tant in therapeutic applications due to cell wall permeability limitations. In general
anything greater than 200 nm will not be able to enter the cell through a simple
diffusion process and anything smaller than 30 nm will be evacuated prematurely
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Figure 3.1: (A) Schematic representation of the built system, showing positioning of the dyes
on the surface of the nanoparticle. (B) Emission and absorption patterns of donor dye (oxadiazole
derivative - azOx) measured in tetrahydrofuran; excitation at 335 nm. (C) Emission and absorption
patterns of acceptor dye (naphthalimide - Naph) measured in tetrahydrofuran; excitation at 400
nm.
through the urinary system[100, 103, 104]. In this study we used nanoparticles
with an average size of 60 nm, and a poloxamer with a theoretical fully extended
length of almost 15 nm, which yields a total theoretical maximum size of approxi-
mately 90 nm, which is within the desired size range for medical applications.
Figure 3.2 presents the photoluminescence (PL) at 20 ◦C in water of the par-
ticles with the dual dye-modification (PA/azOx/azPlurNaph) at a grafting density
around 0.5 dye molecules per nm2, as well as two additional sets of nanoparticles
with similar grafting densities of dyes. One set of the nanoparticles was prepared
with azOx and a poloxamer that had not been modified with the naphthalimide
dye (PA/azOx/azPlur), while the other set of particles had been modified with
only the azPlurNaph dye (PA/azPlurNaph). The poloxamer was attached to the
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first set of particles to ensure a similar environment for the azOx dye. For the
PA/azOx/azPlur, the excitation energy at 335 nm is within the absorbance window
of the azOx dye and the particles exhibit an oxadiazole-based emission (cf. Figure
3.1B) at 400 nm. The excitation wavelength is outside the absorbance window of
the naphthalimide dye (cf. Figure 3.1C), and the PA/azPlurNaph did not exhibit
any appreciable emission, though exciting the particles at 400 nm did result in an
naphthalimide-based emission (spectra not presented). When excited at 335 nm,
the PA/azOx/azPlurNaph particles did exhibit emission characteristics of both the
oxadiazole and naphthalimide dyes, indicating that energy transfer is taking place
from the azOx to the azPlurNaph dyes, though there is an incomplete transfer since
the emission of the oxadiazole-based dye is still present in the spectra.
Figure 3.2: Photoluminescence of particles: (1) modified with oxadiazole dye (azOx) and polox-
amer (◦); modified with poloxamer terminated with naphthalimide dye (azPlurNaph) (—); (3)
modified with both dyes azOx and azPlurNaph (•). All particles excited at 335 nm. Chromophores
density for all samples is similar. Emission for azOx modified nanoparticles at 400 nm was matched
to the emission of dual modified nanoparticles for better energy loss representation. azPlurNaph
particle density was matched to azOx particle density. Measurements taken at room temperature.
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Utilizing FRET theory[64] and the photoluminescence (PL) response of the
PA/azOx/azPlurNaph particles (cf. Figure 3.2-3), the distance and energy transfer
efficiency between the dyes were calculated. The FRET efficiency for the system
was calculated using the half-lifetimes of the two sets of the nanoparticles. The first
set contained the donor dye (azOx) and the poloxamer, the second set contained
both the donor dye (azOx) and the acceptor dye (azPlurNaph). By comparing the
ratio of the half-lifetime of the donor alone and the half-lifetime of the donor in the
presence of the acceptor, the FRET efficiency was calculated[64, 65]. Based on the
emission and absorption spectra of azOx and azPlurNaph, the Fo¨rster distance was
found to be 3.54 nm with a transfer efficiency of ca. 70 % at 20 ◦C for the given
pair of dyes.
Figure 3.3: (A) Optical image of neat Pluronic-L64 (poloxamer/water) solution at room tem-
perature (left vial) and at 60 ◦C (right vial) (LCST is 58 ◦C). (B) Dependence of micelles size and
number of micelles formed by Pluronic-L64 in water with solution temperature (measured through
dynamic light scattering).
The component selection of the particles was designed to maximize the FRET
efficiency between the fluorophores. To achieve a high level of energy transfer
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between a pair of dyes, emission of the donor has to have a significant spectral
overlap with the absorption of the acceptor[64]. The naphthalimide (azPlurNaph)
and oxadiazole (azOx) dyes employed in this effort satisfy this requirement; there
is almost 100 % overlap of the donor emission with the absorption of the acceptor
(cf. Figures 3.1B,C). The grafting density was determined to be ca. 0.54 molecules
per nm2 for the donor dye (azOx) and 0.39 molecules per nm2 for the acceptor
dye (azPlurNaph). Since FRET is very sensitive to the distance between dyes, it is
expected that by controlling this distance one can achieve control over the extent
of FRET[64].
Poloxamer copolymers are known to change their coil dimensions as a func-
tion of temperature, and these changes are reversible and predictable for a given
composition of the copolymer[31]. The Pluronic-L64 poloxamer exhibits significant
changes in its end-to-end distance with temperature variations and was employed
as a means for modulating the distance (and FRET) between the donor/acceptor
dyes. In Figure 3.3A, a neat Pluronic-L64/water solution goes from a transpar-
ent solution to a turbid one as the temperature passes through its LCST, while
Figure 3.3B presents the micelles dimensions of the neat Pluronic-L64 poloxamer
with temperature variations as analyzed through dynamic light scattering (DLS)
procedures[105]. The size of the neat poloxamer appears to exhibit a dramatic in-
crease between 50 ◦C and 60 ◦C, going from ca. 50 nm to 300 nm, which coincides
with the lower critical solution temperature (LCST) temperature of the polymer
(58 ◦C). In this temperature range, one can expect to see the largest changes in
the FRET efficiency of the PA/azOx/azPlurNaph particles to occur. The DLS results
are not indicative of the size of the copolymer coils, but are essentially measuring
the scattering of the polymer coils as they go from a miscible state (low scattering
entity) to a highly scattering dispersion with the increase in temperature.
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Figure 3.4: Photoluminescence spectra of PA/azOx/azPlurNaph particles at various temperatures.
The donor dye is azOx with a peak emission ca. 400 nm, while the acceptor dye is azPlurNaph with
a peak emission ca. 550 nm. The LCST of the poloxamer, on which the acceptor dye is attached at
the end, is 58 ◦C. Particles dispersed in deionized water and graphs are shifted for clarity. Excitation
energy at a wavelength of 335 nm.
The photoluminescence dependence on temperature of the PA/ azOx/ az-
PlurNaph particles is presented in Figure 3.4. At 20 ◦C, the PL response of the
particles indicates that both dyes are emitting when excited by a 335 nm excitation,
as is expected from the previously presented PL study at 20 ◦C (cf. Figure 3.2).
This excitation wavelength is within and outside the absorption regime of the azOx
dye and azPlurNaph dye, respectively, and should only result in emission from the
donor dye. Nonetheless, the emission profile of the particle clearly has the signa-
ture of the azPlurNaph dye, suggesting that there is energy transfer taking place
from the donor to acceptor dye. Subsequent scans at higher temperatures indicate
a diminishing energy transfer until ca. 60 ◦C where minimal energy transfer is dis-
cernible in the spectral response of the particles. The increase in the emission at
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ca. 400 nm (azOx) and the decrease in the emission at 580 nm (azPlurNaph) is
indicative of a reduction in energy transfer from the oxadiazole to the naphthalim-
ide dye. This change is most pronounced within the 50 - 60 ◦C range and suggests
that the separation distance of the two dyes is becoming larger, thereby frustrating
FRET[64]. This temperature range is also within the LCST range for the poloxamer.
Surprisingly, according to previous studies on poloxamer behavior, it was expected
that as the temperature increased, the poloxamer end-to-end distance would de-
crease, giving rise to a more compact coil packing[31]. This decrease in the size of
the copolymer was expected to bring the two dyes closer together, resulting in an
increase in the FRET efficiency, which was not observed.
Figure 3.5: FRET efficiency (◦) and calculated distance between the azOx and azPlurNaph dyes
(•) for the PA/azOx/azPlurNaph particles system (in water) presented in Figure 3.1.
Dye’s quantum yield can change at different temperatures, thus influencing
the intensity of the emission peak at elevated temperatures. To check whether this
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change was not a main factor behind observed results, quantum yield dependence
on the temperature for both dyes was measured and was found to be much smaller
than the observed changes, further suggesting that the main mechanism behind the
observed emission change is FRET.
To check quantum yield dependence on the temperature, dyes were dis-
solved in a good solvent with high enough boiling temperature to measure the
change of quantum yield over the widest possible temperature range. Based on
the available literature data and properties of Ethanol, this solvent was chosen as a
reference solvent. Ideally quantum yield dependence on the temperature should be
measured from the same solvent as the device, but because both dyes are insoluble
in water alternative solvent had to be chosen. Measurement of the quantum yield
requires a reference dye, so anthracene was selected. According to the standard
procedure to measure quantum yield emission and absorption spectra of the dye of
interest should be compared to the emission and absorption spectra of the reference
dye, which absorbs in the similar range as the investigated dye[106]. Anthracene
has good solubility in ethanol, and its quantum yield is well established for this
solvent. Additionally, absorbance and emission of anthracene are similar to the two
dyes used in this chapter, thus making anthracene a good candidate for a reference
dye role.
Procedure for quantum yield determination was as follows: first UV/Vis ab-
sorbance spectrum of ethanol was recorded. This spectra was used to correct the
rest of the samples for any background absorbance effects from the solvent, the cu-
vette, or the instrument. Then for each dye five concentrations were prepared en-
suring that absorbance maximum for all samples was below 0.2 and the increment
in the absorbance between each concentration was 0.04. After the absorbance for
all 5 concentrations and for all dyes were recorded, the fluorescence of each solu-
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tion was recorded. For each dye based on the recorded data a graph of fluorescence
intensity versus absorbance was plotted. If the obtained graph was close to the
straight line then the data was considered to be reliable and slope of the line was
calculated. Obtained lines for two temperature are presented on Figure 3.6
Figure 3.6: Dependence of fluorescence emission on the absorbance for Anthracene, Naphthal-
imide and Oxadiazole. Based on these graphs, quantum yield dependence on the temperature for
Naphthalimide and Oxadiazole dyes was determined.
Slope of the lines for each dye is proportional to the quantum yield of the
dye. To determine the absolute value of the quantum yield for each dye ratio of
the slope gradients of the unknown sample to the anthracene were multiplied by
the literature value of anthracene quantum yield. Because all measurements were
done from the same solvent, there was no need to account for the refractive index
difference between the runs. As can be seen on the Figure 3.6, there is almost no
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change in the slope for the anthracene dye indicating that quantum yield for this
dye has not changed much in the investigated temperature window and thus can
be used as a reference dye for both temperatures.
Both of the dyes used in this study showed slight deviations in the slopes
when temperature was changed from 20 ◦C to 40◦C . According to the literature[106]
quantum yield of anthracene at 20◦C is 0.27, calculated slopes for anthracene were
12.1E6 at 20◦C with correlation coefficient R=0.9944 and 12.5E6 at 40◦C with
correlation coefficient R=0.9953, calculated slopes for oxadiazole were 26.7E6 at
20◦C with correlation coefficient R=0.9996 and 31.3E6 at 40◦C with correlation co-
efficient R=0.9922, calculated slopes for naphthalimide were 1.65E6 at 20◦C with
correlation coefficient R=0.9698 and 1.34E6 at 40◦C with correlation coefficient
R=0.9704. Based on these numbers a 20◦C change in temperature causes 6 and 5
percent change in the quantum yield of oxadiazole and naphthalimide respectively,
or less than 0.3 percent per degree. This change is much smaller than the observed
2 percent change seen for the device, thus supporting the idea that FRET is the
main mechanism that is causing observed emission changes. To calculate quantum
yield (QY) the following equation was used[106]:
QYunknown = QYre f erence ∗ slopeunknownslopere f erence ∗
η2unknown
η2re f erence
where QY is quantum yield of either reference dye or dye of interest, slope
values are found based on the graphs described above, η is refractive index of the
solvent from which emission and absorbance for the dye were collected. Since all
three dyes were recorded from Ethanol, the last fraction in the formula was equal
to 1.
Using the ratio of peak areas for azOx and azPluroNaph dyes for dual dye
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modified nanoparticles at various temperatures referenced to the FRET efficiency
at 20◦C as calculated based on the lifetime measurements for the system, the FRET
efficiency and corresponding distances between the dyes over a range of temper-
atures were calculated[64] results are presented in Figure 3.5. The distance was
found to change from 3.1 nm to 3.9 nm in the 20◦C - 65◦C temperature range,
which translates into a change of the FRET efficiency between 70% - 36%. The
highest rate of change in the inter-dye distance and corresponding FRET efficiency
was observed at temperatures near the LCST temperature of the poloxamer (i.e. 58
◦C ).
Figure 3.7: Proposed mechanism of the variation in photoluminescence response with tempera-
ture of PA/azOx/azPlurNaph particles (cf. Figure 3.1A). At temperatures below LCST, the PPO block
forms a hydrophobic domain with loose packing which allows the naphthalimide dye to sequester
into its domain, but with a temperature rise above LCST, the PPO domain packs more densely forc-
ing the naphthalimide dye from the domain, resulting in an increase of the distance between donor
and acceptor dyes.
We speculate that the simple end-to-end distance argument of the poloxamer
to account for FRET efficiency does not account for the poloxamer’s unique environ-
ment created when it transitions from a coil to an extended structure[30, 88]. Previ-
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ous studies on block copolymer behavior have found that these copolymers can fold
their free ends back into the polymer matrix under specific conditions[107]. This
fact combined with the hydrophobicity of the naphthalimide dye suggests that in
the proposed system poloxamer end with naphthalimide will be flipped back inside
of the poloxamer matrix positioning the dye in the propylene oxide block volume.
Propylene oxide block creates a hydrophobic environment and thus forms
preferred conditions for free end flipping while bringing two dyes closer together.
We speculate that at lower temperatures, the free end of the poloxamer, which con-
tains the hydrophobic naphthalimide dye, folds itself back into the polymer matrix,
schematically presented in Figure 3.7. This folding of the poloxamer brings the two
dyes closer together (since the mobility of the oxadiazole dyes is limited), result-
ing in an enhanced FRET efficiency. As the temperature approaches the LCST of
the poloxamer used, packing of the PPO block becomes too dense[31, 108, 109]
and, as a result, the naphthalimide can not fit inside the polymer matrix and is
pushed to the outer edge, increasing the distance between the dye and the surface
of nanoparticle along with oxadiazole dye, which results in the observed reduced
FRET efficiency.
Using the characteristic ratios of ethylene oxide (EO) and propylene oxide
(PO) segments of the poloxamer copolymer, the theoretically calculated end-to-end
distance of the chain in a theta solvent was calculated to be ca. 4.9 nm[61]. The
theta condition is defined as the state when a polymer can not distinguish between
itself and its surrounding solvent molecules and adopts relatively “compact” confor-
mations that are defined by local interactions. This calculated value was 58 % to 25
% greater than the shortest and longest, respectively, distance between the dyes ob-
tained from the FRET calculations and supports the concept that the naphthalimide
end of the copolymer is folded back into the polymer matrix.
35
Previous studies have shown that hydrophobic drugs have a tendency to
concentrate in the core of a poloxamer PPO block[93, 99, 110, 111]. Additionally,
previous reports indicate that hydrophobic drugs sequestered in the PPO domain
of a poloxamer can be ejected as the temperature is raised above the LCST of the
copolymer[93]. As indicated previously, we speculate for the PA/azOx/azPlurNaph
particles at temperatures below the LCST, the PPO block of the poloxamer forms
a hydrophobic pocket around the PA particles, which attracts the naphthalimide
dye[31], since this layer provides a more favorable condition relative to the aqueous
environment outside of these PPO layers (schematically presented on Figure 3.7).
At temperatures higher than the LCST, the packing of the PPO block becomes too
dense[95, 91, 13] to accommodate the naphthalimide dye inside of the layer and
the dye is forced out to the outer edge of the polymer matrix, away from the donor
dye. This increase in the distance between azOx and azPlurNaph dyes leads to a
decrease in the FRET efficiency.
The role of the poloxamer was investigated by modifying a set of parti-
cles with a azide fictionalized naphthalimide dye (azNaph) instead of azPlurNaph.
These PA/azOx/azNaph particles did not exhibit any emission when dispersed in
water and excited at a 335 nm or 400 nm excitation wavelength, indicating that
there is fluorescence quenching when the particles do not have the poloxamer
on the particles. Dispersing the particles in tetrahydrofuran (THF), a solvent in
which both dyes are miscible, resulted in the reappearance of the typical spectra
of the dyes. This observation further suggests that changes in the poloxamer state
is the main mechanism responsible for the changes in emission patterns for the
PA/azOx/azPlurNaph particles when in an aqueous state.
To test the proposed mechanism, a small molecule study was performed with
just the azOx, azPlurNaph, and the unmodified poloxamer. In this system, the
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Figure 3.8: Normalized integrated emission attributed to azOx (5) and azPlurNaph (4) dyes in
small molecule study performed with azOx, azPlurNaph, and the unmodified poloxamer in deionized
water. Sample was repeatedly heated to 65◦C (LCST of poloxamer was 58◦C) and then allowed to
cool down. For the donor dye (azOx), the emission was integrated between 340 nm and 480 nm
while for the acceptor dye (azPlurNaph) the emission was integrated between 510 nm and 590 nm.
The sample was excited at a wavelength of 335 nm.
three components were placed in deionized water and excited at a wavelength of
335 nm while the temperature was cycled between 20 ◦C and 65 ◦C, all the while
observing the emission of the system. The ratio of the dyes was 1 to 1 and total
concentration of poloxamer copolymer was 15 mg/mL. The results of the study
are depicted in Figure 3.8, where the integrated emission attributed to the azOx
and azPlurNaph dyes is presented relative to time and temperature. Initially at
temperatures around 20 ◦C, there is only an emission from the azPlurNaph dyes
(acceptor) that is replaced by an emission from the azOx dye (donor) when the
system is heated to 65 ◦C. We attribute this to the fact that the system initially
exhibits FRET between the dyes, at room temperature, and then the energy transfer
is disturbed when the system is heated to 65 ◦C, above LCST of the poloxamer. This
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emission switching from the azPlurNaph dye to the azOx dye as the temperature is
cycled back and forth was repeated multiple times with four cycles being presented
in Figure 3.8.
There is a clear emission switching from the donor dye to the acceptor dye
with the temperature cycling. The small molecule model system exhibited the same
patterns of emission as the PA/azOx/azPlurNaph particles, but there are two differ-
ences. First, the emission of the small molecule system is time dependent (decreases
with time) due to the precipitation of the dyes from solution, supporting the need
for the particles acting as a stabilizing carrier. Second, the FRET efficiency variation
of the small molecule system is much more prominent as compared to the parti-
cles. It is hypothesized that almost complete 0 % to 100 % FRET efficiency change
exhibited by the small molecule system is due to the much higher mobility of both
dyes as compared to the system where the dyes are attached to the nanoparticles.
Performing the same study without the poloxamer resulted in no emission since the
dyes are hydrophobic and presumably precipitate from solution quickly. Clearly, the
poloxamer plays an important role in sequestering the dyes in an aqueous environ-
ment, and this role is highly temperature dependent.
3.3 Conclusion.
In the present work, we achieved control over the changes in FRET efficiency
of an emissive colloidal system through the attachment of a donor dye (azOx) di-
rectly to the particle surface, while an acceptor dye (azPlurNaph) was attached to
the surface of particles through a poloxamer copolymer. The poloxamer (Pluronic-
L64) was utilized as the temperature responsive component to regulate the distance
between the dyes. The current system achieved its maximum variation in FRET ef-
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ficiency (∆εFRET ≈20 %) in the temperature range of 49 ◦C to 60 ◦C, which is in
the region of the cloud point of the poloxamer (LCST) used in this study, though
other poloxamers with differing LCST temperatures could be utilized to tune the
temperature range of the colloidal device.
3.4 Experimental methods
3.4.1 Materials and Reagents
All reagents were purchased from Sigma-Aldrich with at least 97% purity
level. Deionized water was obtain from Barnstead Nanopure Diamond water system
and had 18.2 MOhm resistance. Spectroscopic grade of tetrahydrofuran was used
to measure absorbance and emission of the dyes.
3.4.2 Characterization
1H spectra were recorded on JEOL ECX-300 spectrometers (300MHz for
proton). Chemical shifts for protons are reported in parts per million downfield
from tetramethylsilane and are referenced to the carbon resonances of the solvent
(CDCl3: δ 7.26), 2 mg/mL solutions were used to record 1H spectra. Photolumi-
nescence (PL) spectra were collected using Photon Technology International (PTI)
spectrometer equipped with Hamamatsu C9940-01 detector and Jobin-Yvon Fluo-
rolog 3-222 Tau spectrometer. Lifetime measurements were collected using a Jobin-
Yvon Fluorolog 3-222 Tau spectrometer. Photoluminescence dependence on tem-
perature was measured using PTI spectrometer equipped with Quantum Northwest
TC125 temperature control unit using 10 mm quartz cuvette. Nanoparticle size was
checked using Coulter N4Plus dynamic light scattering (DLS) instrument using 10
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mm plastic cuvette. UV/Vis spectra was obtained using Perkin Elmer Lambda 850
spectrometer using 10 mm quartz cuvette.
3.4.3 Nanoparticle preparation
Emulsion polymerization was performed in a single necked round bottom
flask (100 mL) with magnetic stirring. Potassium persulfate (70 mg) was dissolved
in water (29 mL) and nitrogen was purged through the solution for 15 minutes.
Sodium dodecyl sulfate solution (29% in H2O, 0.4 mL) was added to the flask un-
der nitrogen. The resulting solution was stirred and placed in a preheated bath
at 70 ◦C for 2 minutes, then a degassed solution of propargyl acrylate (2 mL) and
divinylbenzene (0.1 mL) were added to the main reaction. The mixture was stirred
at 70 ◦C under nitrogen for 90 minutes. Magnetic stirrer was used to mix the reac-
tion, speed of steering was set at 400 rpm. Size of the magnetic stirrer was selected
such that ensured creation of a stable vortex that was not reaching bottom of the
solution. If the conditions of stirring were not met resulting nanoparticles had very
wide size distribution rendering them useless for the intended application. After 90
minutes at 70◦C reaction was cooled, then filtered using paper filter; followed by
purification by dialysis using Spectra/Por Dialysis membrane with MWCO 50000 for
3 days at 40 ◦C in a 20 liter dialysis bath filled with 18.2 MOhm resistance deionized
water, with water being changed every 8 hours. Nanoparticles were characterized
using DLS, median size was 60 nm with a standard deviation of 10 nm. The final
emulsion contained 45 mg/mL of nanoparticles.
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3.4.4 Oxadiazole-N3 preparation
Oxadiazole-N3 was synthesized and purified prior to use according to litera-
ture procedure[41]. Synthesis consisted of three steps:
2-(4-Methylphenyl)-5-(1-naphthyl)-1,3,4-oxadiazole (Figure 3.9A). A mixture
of 5-(4-methylphenyl)-2H-tetrazole (2.5 g, 15.6 mmol), 1-naphthoyl chloride (3.27
g, 17.2 mmol) and pyridine (30 mL) was stirred and refluxed for 5 h. After cool-
ing to room temperature, the mixture was quenched with water to precipitate the
product. White crystals were filtered and dried on air to give the titled compound.
Yield: 4 g (90%). 1H NMR ((CD3)2SO2) 2.43 (s, 3H), 7.46 (d, 2H), 7.667.80 (m,
3H), 8.10 (m, 3H), 8.24 (d, 1H), 8.40 (d.d, 1H), 9.19 (d,).
2-[4-(Bromomethyl)phenyl]-5-(1-naphthyl)-1,3,4-oxadiazole (Figure 3.9B). A
solution of 2-(4-methylphenyl)-5-(1-naphthyl)-1,3,4-oxadiazole (1 g, 3.39 mmol),
N-bromosuccinimide (0.622 g, 3.49 mmol) and benzoyl peroxide (0.03g, 0.12 mmol)
in chloroform (40 mL) was refluxed for 4 h to result in 50% conversion of the
starting compound as determined by 1H NMR. N-bromosuccinimide (0.622 g, 3.49
mmol) and benzoyl peroxide (0.02 g, 0.08 mmol) were added again and the solu-
tion was refluxed for 5 h. The solvent was evaporated and the residue was washed
with water, filtered, dried on air and recrystallized from acetone to produce white
crystals. Yield: 0.86 g (67%). 1H NMR (CDCl3) 4.55 (s, 2H), 7.567.65 (m, 4H),
7.72 (m, 1H), 7.95 (d, 1H), 8.06 (d, 1H), 8.19 (d, 2H), 8.28 (d.d), 9.28 (d, 1H).
2-[4-(Azidomethyl)phenyl]-5-(1-naphthyl)-1,3,4-oxadiazole (Figure 3.9azOx).
A mixture of 2-[4-(bromomethyl)phenyl]-5-(1-naphthyl)-1,3,4-oxadiazole (0.8 g,
2.19 mmol) and sodium azide (0.17 g, 2.61 mmol) in dimethylformamide (10 mL)
was heated and stirred at 80 ◦C for 8 h. After cooling to room temperature, the mix-
ture was quenched with water and cooled to 5 ◦C . The solid was filtered, washed
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with water and dried on air to give white crystals. Yield: 0.65 g (76%). 1H NMR
(CDCl3) 4.47 (s, 2H), 7.53 (d, 2H), 7.62 (m, 2H), 7.72 (m, 1H), 7.95 (d, 1H), 8.06
(d, 1H), 8.23 (d, 2H), 8.28 (d.d, 1H), 9.29 (d, 1H).
Figure 3.9: Scheme of AzOx dye synthesis.
3.4.5 Naphthalimide preparation
Naphthalimide was synthesized prior to use according to literature proce-
dure [112]. 0.67 g of Naphthalic anhydride was mixed with 340 mg of formamid
in 15 mL of methanol using 35 mL pressurized reaction vial. Vial was hermetically
closed with Teflon screw and heated to 120◦C for 40 hours. Solvent was evaporated
under vacuum and resulting product was analyzed using 1H nuclear magnetic reso-
nance (NMR) technique. Obtained 0.65 g of brown powder. 1H (CDCl3) δ 7.93 (m,
1H), 8.19 (s, 1H), 8.22 (m, 1H), 8.47 (m, 2H).
Second step was addition of piperidine ring. Product from previous step
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was mixed with piperidine in 8 mL of dimethyl sulfoxide (DMSO) in 25 mL round
bottom flask equipped with condenser. Reaction was mixed at 85◦C for 20 hours.
20 mL of deionized water was added to dissolve byproducts and DMSO, 10 mL of
dichloromethane was added to dissolve product. Mixture was transferred into sep-
aration funnel and was vigorously shaked for 2 minutes. After mixture had phase
separated, typically this process required 2 to 5 minutes, lower organic layer was
collected into Erlenmeyer flask. 20 mL of deionized water were added to the sepa-
rated organic layer and mixture was again transferred into clean separation funnel.
Process of mixing and separation was repeated as described above. After last sepa-
ration 5 g of sodium sulfate was added to organic layer to remove remaining water.
Mixture was mixed for 3 minutes and filtered through paper filter. Organic layer
was evaporated under reduced pressure and checked with 1H ((CDCl3) δ 1.66 (m,
6H), 1.89 (m, 4H), 7.68 (m, 1H), 8.49 (m, 4H)), obtained 0.65 g of yellow powder.
This powder was used in Poloxamer-N3 modification process as described below.
Scheme of reaction is shown on Figure 3.10.
Figure 3.10: Scheme of naphthalimide dye synthesis.
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3.4.6 Poloxamer modification
MeSO2-pluronic-L64. Pluronic-L64 (3.14 g, 1.064 mmol) was dissolved in dry
dichloromethane (DCM) (10 mL), triethylamine (0.132 g, 1.3 mmol) was added to
the solution. The obtained solution was stirred at room temperature for 15 minutes
to ensure good mixing of the components. Methanesulfonyl chloride (62 mg, 0.543
mmol) was dissolved in 2 mL of dry dichloromethane and added drop-wise to the
reaction mixture over 3 minute period. Temperature of the reaction mixture was
monitored while methanesulfonyl chloride was added, if the reaction started to
warm up the rate at which methanesulfonyl chloride was slowed or even stopped
completely until the reaction had cooled down to room temperature.
After all methanesulfonyl chloride was added reaction mixture was stirred
for 6 hours at room temperature. After 6 hours 20 mL of water was added to
the reaction mixture to remove triethylamine chloride and any other water soluble
contaminants. Mixture was vigorously shaked for 2 minutes and then left for 20
minutes to allow phase separation process between water and DCM to complete. If
after 20 minutes no clear phase boundary was observed 20 mg of sodium chloride
was added to the mixture and again shaked vigorously for 2 minutes or until all
sodium chloride was dissolved. After this mixture was again left to stand for 20
minutes to allow water and DCM to phase separate. Bottom layer was collected
and 20 more mL of deionized water was added to it. Mixture again was vigorously
shaked for 2 minutes followed with separation as discussed above. This process
was repeated 3 times. After 3 time DCM layer was pored over 3 g of sodium sulfate
salt. Obtained mixture was mixed for 2 minutes or until all cloudiness was cleared.
After this mixture was filtered through paper filter to remove sodium sulfate salt
and evaporated under reduced pressure. Yield 3.1 g (95%), clear oil. This product
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was used in the next step without further purification. 1H NMR (CDCl3) δ 1.11 (m,
96H), 3.06 (s, 3H), 3.38 (m, 32H), 3.52 (m, 64H), 3.63 (m, 98H).
Pluronic-L64-N3. Sodium azide (195 mg, 3 mmol) was added into solution
of MeSO2-pluronic-L64 (3.1 g, 1.03 mmol) in dimethylformamide (DMF) (10 mL).
The mixture was stirred and heated to 80 ◦C for 3 hours. After cooling the mix-
ture was extracted with DCM and washed with water 2 times following the same
procedure as for MeSO2-pluronic-L64. The organic layer was separated, dried with
Na2SO4, filtered and evaporated under reduced pressure. Yield 2.27 g (75%), clear
oil. Pluronic-L64-N3 was used in the next step without further purification. 1H
NMR (CDCl3) δ 1.07 (m, 96H), 3.34 (m, 32H), 3.48 (m, 64H), 3.59 (m, 98H).
MeSO2-pluronic-L64-N3. Pluronic-L64-N3 (1 g, 0.34 mmol) was dissolved in
dry DCM (3 mL), then triethylamine (42 mg, 0.408 mmol) was added. The solu-
tion was stirred at room temperature and methanesulfonyl chloride (78 mg, 0.68
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mmol) in 2 mL of dry DCM was added drop-wise following the same precautions
as described above. The reaction was stirred at room temperature for 6 hours, fol-
lowed by extraction with DCM and washed with water as described above. The
organic layer was separated, dried with Na2SO4, filtered and evaporated under re-
duced pressure. Yield 0.7 g (65%), clear oil. This product was used in the next step
without further purification. 1H NMR (CDCl3) δ 1.11 (m, 96H), 3.07 (m, 3H), 3.38
(m, 32H), 3.52 (m, 64H), 3.64 (m, 98H).
azPlurNaph. The mixture of MeSO2-pluronic-L64-N3 (0.7 g, 0.22 mmol),
naphthalimide (100 mg, 0.36 mmol) and potassium carbonate (80 mg, 0.58 mmol)
in acetone (15 mL) was stirred and refluxed for 48 hours. The mixture was filtered,
and the filtrate was evaporated under reduced pressure; the residue was extracted
with DCM and washed with water using the same procedure as described above.
The organic layer was separated, dried with Na2SO4, filtered and evaporated under
reduced pressure. Yield 0.58 g (80%), yellow oil. 1H NMR (CDCl3) δ 1.11 (m,
96H), 1.70 (m, 6H), 1.86 (m, 10H), 3.38 (m, 32H), 3.52 (m, 64H), 3.62 (m, 98H),
7.14 (m, 2H), 7.65 (m, 2H), 8.31-8.54 (m, 8H).
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3.4.7 Nanoparticle modification
Nanoparticle modification was performed using the azide alkyne Huisgen cy-
cloaddition reaction (Click chemistry). A typical procedure was used as described
elsewhere[41]. In short, copper(II) sulfate (CuSO4) (2 mg, 8 µmol) was dissolved
in 2 mL of deionized water and added to the propargyl acrylate nanoparticles sus-
pension in water (2 mL) that contained 45 mg of dry propargyl acrylate cores. The
solution of azOx (2 mg, 7 µmol) in the mixture of tetrahydrofuran (THF) (2 mL)
and methanol (4 mL) was added to the suspension of nanoparticles. Reaction vessel
was purged with nitrogen for 5 minutes while stirring with magnetic stirrer, then
sodium ascorbate (10 mg, 50.5 µmol) was added. The mixture was stirred at 28◦C
for 24 hours, nitrogen was purged at slow rate over the top of solution; then the
solution of azPlurNaph (22 mg, 7 µmol) in THF (2 mL) was added. Then the solu-
tion of CuSO4 (2 mg, 8 µmol) in water (2 mL) was added. The reaction was stirred
and purged with nitrogen through solution for 5 minutes, then sodium ascorbate
(10 mg, 50.5 µmol) was added. The reaction continued at 28 ◦C for 24 hours under
nitrogen purge over the top of solution.
The reaction mixture was centrifuged at 10000G for 5 minutes. All solvent
and dissolved reagents were decanted while leaving precipitated nanoparticles on
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the bottom of the centrifuge tube. Dye content in the supernatant solution was
measured based on the UV/Vis absorption utilizing Beer-Lambert Law: dependence
of absorbance maximum on the dye concentration. The calculated amount of the
dye was subtracted from the loaded amount of the dye to find the encapsulated
quantity for both dyes.
Separated nanoparticles were redispersed in the mixture of THF:Methanol
1:1 (20 mL) using a vortex shaker set to maximum speed. If after 1 minute on the
shaker big aggregates were still present, the centrifuge tube was placed in the soni-
cation bath for 15 minutes. After sonication, suspension was again agitated using a
vortex shaker for 15 seconds set to maximum speed. If aggregates still were visible,
then sonication process was repeated. When all aggregates were dispersed, sus-
pension was centrifuged at 7000G for 10 minutes. After centrifugation all solvent
was again decanted, leaving nanoparticles in the centrifuge tube and then the dye
content in supernatant was measured and added to the amount of the dye as was
found after first centrifugation.
This purification process was repeated 5 times to remove all impurities. If
after the 5th time the peak for any of the dyes was still detectable by UV/Vis, the
cleaning process was repeated again until UV/Vis was no longer able to detect the
dye in supernatant solution. The content of unreacted dyes in the supernatant
solution was monitored by observation of UV/Vis absorption (for azOx peak at 330
nm was monitored, for azPlurNaph peak at 400 nm was monitored). When these
peaks were impossible to identify the cleaning process was considered complete. In
some cases, more than 5 repetitions of centrifugation were required. After the last
centrifugation the nanoparticles were suspended in water (3 mL) and stored in the
dark until further use.
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3.4.8 Grafting density determination
To determine grafting density of the dyes all supernatant solutions from
nanoparticle cleaning process were collected and the dye content in them was cal-
culated using the Beer-Lambert law based on the specific absorption for each dye.
The mass of both dyes in all supernatant solutions was calculated and summed. To
determine the mass of the dye total volume of the collected supernatant after each
step was multiplied by the concentration of the dye in this supernatant solution as
found according to Beer-Lambert law. This sum was subtracted from the loading
quantities of the dyes to calculate mass of the dyes that had reacted. Total surface
area of the nanoparticles was calculated using the assumption that nanoparticles
are perfect mono-disperse spheres with 60 nm diameter. Nanoparticles core size
was determined prior the modification process using dynamic light scattering and
was found to be be 60 nm. To find the final grafting density for each dye total
number of molecules was calculated based on the calculated total mass of the dye
that has reacted, was determined as described above, this total number of molecules
was divided by the total surface area of the nanoparticles to yield grafting density in
molecules per nm2 of the core surface. The final grafting density for oxadiazole-N3
was found to be 0.54 molecules per nm2, naphthalimide-pluronic-L64-N3 complex
0.39 molecules per nm2.
3.4.9 Fluorescence measurements
Sample preparation procedure for fluorescence measurements for dual dye
modified nanoparticles were as follows: portion of the suspension obtained after
cleaning was dispersed in water to achieve nanoparticle density of approximately
0.1 mg/mL, which translates to approximately 1*10−9 mole/mL of dye. All samples
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were allowed 24 hours for equilibration at room temperature prior to any measure-
ment. For each measurement, 3 mL of the nanoparticle suspension in water was
transferred into 1 cm quartz cuvette equipped with stirrer. Prior to conducting a
measurement at a given temperature, the sample was allowed to equilibrate at this
temperature for 15 minutes to ensure that the system has reached equilibrium state.
Experimentally, it was shown that for all temperature ranges, stable emission levels
were reached within 3 to 6 minutes at a given temperature, so allowing an extra 10
minutes is expected to be sufficient for nanoparticles to reach stable equilibrium.
For a single dye modified nanoparticles, concentration of the nanoparticles
was selected based on the emission maximum of azOx modified nanoparticles to
match the emission maximum of oxadiazole peak of dual dye modified nanopar-
ticles. PlurNaph modified nanoparticles concentration was matched to the azOx
nanoparticles. During the preparation of single modified nanoparticles, loading
amounts for both dyes were calculated to match the total number of chromophores
on dual dye modified nanoparticles. This was done to ensure similar separation dis-
tance between dyes for all 3 samples. Matching of the emission maximum for azOx
dye was done to better illustrate that the emission’s peak shape for dual modified
nanoparticles had changed.
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Chapter 4
Control over poloxamer grafting
density
Poloxamer copolymers have a unique set of the responsive and encapsula-
tion properties that find implementation in the biomedical applications. Through
the immobilization of the poloxamer on the surface of a bio-compatible polymeric
nanoparticle, control of the nanocomposite properties was achieved. Precise control
over the composition and, as a result, of the final properties of the nanocomposite
allowed to fine tune the performance of the system build. In this study, an original
nanocomposite of poly(propargyl acrylate) (PA) and poloxamer is synthesized using
graft to approach. Azide-alkyne Huisgen cycloaddition reaction allowed the forma-
tion of a stable bond between the poloxamer and PA nanoparticle and eliminated
the need of an aggressive solvent or toxic, hard to remove, catalyst in the prepara-
tion process. Quick and reliable method to monitor the nanocomposite composition
based on the Fourier transform infrared (FTIR) spectroscopy is described. Addi-
tionally, the system is characterized by dynamic light scattering (DLS), scanning
electron microscopy (SEM), Nuclear Magnetic Resonance (NMR) and BrunauerEm-
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mettTeller (BET) techniques. The developed method allowed us to design a protocol
for synthesis of a device that is free of any unattached poloxamer chains and has a
well defined surface chemistry. FTIR allowed to reliably determine mass ratio of PA
to poloxamer above 1 mass percent of poloxamer in the nanocomposite. Based on
the observed results optimal synthesis and purification procedures are described.
4.1 Introduction
In the recent years, decease treatment using active molecules have seen an
increase in the number of methods developed based on the polymer nanocompos-
ites [20, 113, 114]. One of the investigated approaches is based on the devices built
from the copolymers that tend to self assemble into micelles under certain condi-
tions [115, 116]. Another important approach is based on the core-shell nanocar-
riers [117, 118]. Both of these approaches have their advantages and draw backs.
Some of the challenges of the self assembly carriers is the lack of the control over
the micelles size and the instability of the micelles under certain conditions. Two
common challenges of the core-shell systems are complicated synthesis and lack of
the control over the trigger mechanism. Often core-shell systems lack adjust ability
and are locked for a certain temperature or pH range [119, 120]. As one of the
approaches to achieve the adjust ability of the final properties of the drug carrier
the control over the grafting density of the shell was proposed by Asai [121]. In
this work a synthesis scheme for a nanocarrier that combines advantages of both
approaches while eliminating their disadvantages is discussed.
An important step during the evaluation of any drug carrier is the complete
and accurate characterization of the final assembly. Thus ability to quickly and
reliably characterize the composition of the nanocarrier becomes an essential tool
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when designing a drug delivery vesicle [122]. Fully polymeric systems often present
a challenge in the precise determination of the composition of the nanocomposite
after the final device was assembled and often require a non-standard analytical
approach to determine the final composition of the nanocomposite. The knowledge
about exact nanocomposite composition can provide a valuable incite about the
influence of surface morphology on the final properties of the device and ability to
differentiate between different grafting densities is essential tool in the final testing
of active drug delivery vesicles.
Schematically the difference between various grafting density states is shown
on Figure 4.1. As can be seen from the cartoon, Figure 4.1A, at low GD some of the
core surface is still open, this creates a possibility of drug absorption by the surface
rather than by the active shell layer thus upon trigger event these surface bound
molecules will remain unaffected and even though the loading capacity of such
devices can still be relatively high the release, and specifically triggered release
efficiency will be small. At some intermediate grafting density, Figure 4.1B, all
surface is covered with the active shell, all cargo will be encapsulated inside of the
shell rather than being absorbed by the surface as in first case, and thus upon trigger
event the probability of release is much higher since all cargo is contained within
the active layer of the device.
Graft to method has an upper limit of the grafting density. Only limited
number of the polymer chains can be attached to the surface since the chains that
have been attached first will create a steric barrier for any additional chains. After
reaching certain grafting density using graft to methods speed of reaction decreases
and the dominant factor that determines this speed becomes the ability of the re-
active end to penetrate through the brush formed from already attached to the
surface chains. Combining high loading ratio with long reaction times it is possi-
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ble to reach grafting densities at which polymer chains will start to influence their
neighbors ability to undergo thermal transitions. At such conditions, as shown on
Figure 4.1C, device can start loosing its ability to burst release cargo due to limited
mobility of the polymer chains on the surface.
Figure 4.1: Cartoon illustrating the influence of grafting density on the surface morphology. (A).
Nanoparticle with low grafting density of the shell, lots of open core surface, limited temperature
responsiveness. (B). Nanoparticle with optimal grafting density, all surface is covered, maximum
temperature responsiveness. (C). Nanoparticles with too high grafting density, shell chains restrict
each others movement ability decreasing temperature responsiveness. Cartoon is based on the the-
oretically calculated dimension of the core and poloxamer copolymer representing 0.15, 0.35 and
0.55 poloxamer chains per nm2 grafting density equivalents. Surface decoration with poloxamer was
done using Maya 2016 software package utilizing random surface population with X-gen function
of the software utilizing Mental Ray package version 3.13.1.2.
Poloxamer family of copolymers originally was developed as an effective sur-
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factant for both personal and commercial use [30, 31]. Later these copolymers were
found to be useful in drug delivery application [123, 124]. Copolymer chains con-
sists of a hydrophobic block positioned between two hydrophilic blocks. Such struc-
ture offers a favorable environment for drugs while protecting these drugs from the
aqueous environments. Some of the benefits of poloxamer based systems for med-
ical applications are: their ability to re-sensitize cancer tissue to the drug [98, 34],
decreasing the required drug concentration and as a result decreasing the possi-
bility of the side effects; the ability to prolong the circulation of the devices deco-
rated with poloxamer in the human body [33], allowing ample time for the device
to complete its designed drug delivery mission; the ability to program the tem-
perature of response based on the selection of appropriate commercially available
poloxamer [31] eliminating the need to modify the synthetic procedures every time
a different temperature of response is needed.
Additionally, poloxamer solves the challenge of complex synthesis and allows
the programming of the temperature of the response simply through the use of a
correct copolymer version. Hydroxyl groups on the ends of the copolymer chain
can be substituted with other functional groups making it possible to attach the
poloxamer to the surfaces or to attach active molecules to the poloxamer.
Poloxamers can self-assemble into micelles, but stability of such micelles is
dependent on both temperature and concentration, thus they can disassemble be-
fore reaching their target and the release of the active molecules can occur outside
of the region of interest rendering the treatment ineffective. To solve this challenge
a method is proposed to immobilize the poloxamer on the surface of the propar-
gyl acrylate nanoparticle creating a designed formation, making the hydrophobic
pockets formed by the propylene oxide block stable.
Propargyl acrylate nanoparticles (PAn) besides serving the purpose of the
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inert bio-compatible core [41] helps to solve one more challenge: control over the
size of the drug delivery vesicle. As was shown by Roeder [36] PAn can be readily
synthesized in a wide range of sizes with a narrow size distribution. Control over
the size of the drug delivery vesicle is important because it allows the researcher to
use passive targeting as a mechanism of targeted drug delivery[103]. Cancer tissue
is known to have a higher blood vessel porosity allowing the devices with size range
40-200 nm to concentrate inside of the tissue [125, 103, 104]. Another benefit of
PAn is the ability to use Azide-alkyne Huisgen cycloaddition, also known as Click
chemistry, to attach various molecules to the surface [41, 40]. Click chemistry is a
highly selective and very efficient process with very low sensitivity to impurities and
can be done from a variety of solvents, including water. Use of the Click chemistry
eliminates the need for a complex purification steps before the final assembly of the
device because even if the starting components have some contamination from the
previous synthesis steps, only molecules bearing an azide and an alkyne groups will
react under the reaction conditions. Since Click chemistry does not require complex
hard to remove catalysts or aggressive solvents the post assembly purification can be
done simply through the centrifugation or the dialysis solving the complex synthesis
challenge of other core-shell based systems.
Lastly, the challenges related to nanoparticle characterization is quantifica-
tion of surface chemistry on the final device. In the inorganic core/organic shell
composite systems determination of the grafting density often is made using ther-
mogravimetric analysis (TGA)[126, 127, 128]. TGA is a relatively quick and reli-
able way to determine the ratio of the core mass to the mass of the shell, making
it possible to calculate the number of molecules per nm2 of the surface. For the
organic on organic nanocomposites TGA fails most of the time due to similarities of
the decomposition temperatures of the core and the shell rendering it impossible to
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differentiate between the two.
Various indirect techniques have been developed to estimate the shell density
on the organic nanoparticles[129, 130], and among these methods FTIR offers the
most value and precision[131, 132]. FTIR allows us to detect the functional groups
and assuming that a correlation between the height of two peaks and the ratio of
the groups that correspond to these peaks can be established a quantification can
be achieved[133]. Quantification of the sample using FTIR is not always possible
and some of the prerequisites of the successful quantification are: the ability to
distinctively separate the signals from the bonds of interest; the strong absorption
of the infrared light by these bonds; and the ability to create a model sample with
a well defined ratio of the bonds of interest at a wide mass ratio range.
Quantification of the sample using FTIR is a labor intensive process. First
a calibration curve has to be obtained against which the unknown samples will be
compared. To build a calibration curve a set of the standard samples, at least 3,
more is better, has to be created. These standards have to be chemically identical
to the unknowns and only the ratio of the functional groups of interest should vary.
In the case of the polymer composites, this means that a mix of all components has
to be prepared and the ratio of the components has to be well defined in this mix.
Next step is to record FTIR spectra of all the standards and to measure the absolute
heights of all the peaks of interest. Then using the ratio of peaks a calibration curve
can be built. This curve represents the dependence of the peak ratio to the com-
ponent mass ratio. Comparing the unknown sample peak ratio to the calibration
curve allows us to obtain the information about the mass ratio of the components in
the sample. Combining the mass ratio data with the size of the cores data and the
molar mass of the shell components allows us to calculate the true grafting density
of the nanocomposite. In case of spherical cores simple geometry equations can
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provide the required information about the total surface area (S) in a given mass
of the sample, and in case of a mono-disperse coating knowledge of the molecular
weight (MWshell) of the coating combined with the mass ratio of the shell to the
core yields a number of molecules per nm2 of the surface. Number of the molecules
in the coating can be determined from the following equation:
N =
TMshell
MWshell
Total mass (TMshell) of the shell is obtained based on the mass ratio informa-
tion from the FTIR calibration curve. To convert the number of the shell molecules
into the grafting density (GD) the following equation is used:
GD=
N
S
4.2 Results and Discussion
4.2.1 Nanocomposite assembly
Propargyl acrylate nanoparticles (PAn) were prepared via emulsion poly-
merization and characterized using DLS and SEM according to previously reported
methods [36], target size for the PAn was 30 nm to maintain high mass ratio be-
tween the core and the shell. In short, the emulsion polymerization was carried
out under the following conditions: potassium per-sulfate was added as an initiator
of the polymerization; 15% by mass of the divinil benzene was added to propargyl
acrylate monomer as a cross-linking agent, to create highly rigid cores; tempera-
ture of the reaction was maintained at 75◦C and the reaction was stopped after
90 minutes to prevent hydrolysis of the carbonyl group on the propargyl acrylate.
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Emulsion was followed by a dialysis in 18.2 MOm deionized water to remove any
unreacted monomers, excess of catalyst and surfactant. Emulsion performed under
this conditions allowed to achieve the desired size with a narrow size distribution
that was confirmed by DLS and SEM measurements. To check for aggregates, a col-
umn chromatography was used to separate the sample on fractions according to the
nanoparticles sizes. Analysis of each fraction confirmed that in the analyzed sample
only one nanoparticle size was present, so any aggregation observed on SEM imag-
ing is, most likely, due to the sticking of nanoparticle together during the drying
process, rather than the presence of actual aggregates in the sample.
Azide-alkyne Huisgen cycloaddition, also known as the Click chemistry, was
used to attach the poloxamer chains to the surface of PAn. Control over the feed
ratio and the reaction time allowed us to synthesize the nanocomposite of a desired
composition, schematically the synthesis scheme is shown on the Figure 4.2.
Click chemistry requires that one of the reagents have alkyne group, and the
other to have azide group. PAn has alkyne groups on its surface and does not require
any additional modifications post the purification step. Poloxamer, on other hand,
needs to be modified prior it can be grafted on to PAn. Poloxamer copolymer has
two hydroxyl groups on its ends and at least one has to be replaced with the azide
group. Modification of both ends with the azide group is the easiest synthetic task,
but having two active ends on one polymer chain creates a possibility for double
attachment of the poloxamer chain to the same core or even cross core attachment
leading to a formation of cross-linked matrix with PAn imbedded in it. In order
to prevent this, the feed ration of methanesulfonyl chloride during the first step of
poloxamer modification was limited to 85% of the amount required to replace just
one hydroxyl group. This starvation of the reaction was done to decrease the prob-
ability of the formation of poloxamer chains with azide groups at both ends. 1H
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Figure 4.2: Scheme of nanocomposite assembly. 1 - acryloyl chloride, 2 - propargyl alcohol, 3 -
propargyl acrylate (PA) monomer (distilled under vacuum before polymerization), 4 - Pluronic L-
64, 5 - methyl sulfonyl mono-substituted poloxamer, 6 - azide mono-substituted poloxamer, 7 - final
assemble of PA nanoparticle decorated with poloxamer chains.
NMR was used to monitor the reaction, peak from the methanesulfonyl appeared at
3.06 ppm and integrated at 2.42 to 96 total hydrogen atoms in CH3 group of PPO
block, comparison of 1H NMR spectra of the stock poloxamer and the methanesul-
fonyl modified poloxamer is shown on Figure 4.3A. The ratio of the area of these
peaks translates into 80% conversion of one end of the poloxamer. Total number of
PPO groups in the chain is 32, number of methanesulfonyl groups according to 1H
NMR is 0.8 groups per one poloxamer chain. This means that there is still at least
20% of unmodified poloxamer left in the mix, but because it does not contain an
azide group it can not participate in the Click reaction and thus can be removed af-
ter it. The total yield of the poloxamer modification reaction measured by the final
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amount of the product obtained was 89%. The second step was the substitution of
the methanesulfonyl group with the azide group. For this step, excess of the sodium
azide was used, the reaction was considered complete when 3.06 peak in 1H NMR
was undetectable by the instrument, spectra is shown on Figure 4.3B.
Figure 4.3: Poloxamer 1H NMR. A Methyl sulfonyl modified poloxamer. B Azide modified polox-
amer.
Combination of low feed ratio with dilute conditions creates a favorable ther-
modynamic conditions that resulted in the mix of unmodified and one end modified
poloxamer. This step simplified the synthetic route through the elimination of any
post synthesis separation steps. The strive to minimize the waste of the poloxamer
will mean significant increase in the purification costs and since poloxamer copoly-
mers are the cheapest component in the device it is economically not feasible to
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attempt to reach 100% conversion on the first step.
4.2.2 Grafting density determination
Precise determination of the achieved shell density is a required step for any
future investigations with the PAn - poloxamer nanocomposite. Thermogravimetric
Analysis (TGA) is a typical method to determine grafting density of a polymer shell
on the surface of the nanoparticle. For PAPN TGA method failed due to the similar-
ities in the decomposition temperature of the components. For propargyl acrylate
- poloxamer pair FTIR proved to be the best alternative method to determine mass
ratio of the components. Propargyl acrylate has strong peaks at 1150 cm−1 and
1728 cm−1, while poloxamer has a sharp and strong peak at 1100 cm−1. The differ-
ence between the 1150 and 1100 peaks is big enough for the instrument to reliably
distinguished the two. Experimentally it was determined that instrument is capa-
ble to reliably distinguish down to 1% of the poloxamer by mass in the mixture
of poloxamer and PAn. FTIR spectra of PAn, poloxamer and the mix of the two is
shown on Figure 4.4.
To be able to measure the mass ratio using FTIR a calibration based on the
known mixture ratio of the poloxamer to PAn was developed. Standard mixtures
with the mass ratios ranging from 1% to 40% of the poloxamer were prepared
and their FTIR spectra were recorded. To prepare standard mixtures, 30 mL of
nanoparticles after dialysis were dried under vacuum at 50◦C . 1000 mg of dry cores
was transferred into medium mortar (3 inch in diameter). 100 mg/mL solution of
poloxamer in water was also prepared. To obtain 1 percent mass ratio of poloxamer
to cores, 0.1 mL of poloxamer solution was added to mortar with nanoparticles and
mixed using a pestle until a uniform paste-like material was formed. Mortar was
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Figure 4.4: FTIR spectra of poloxamer (green line), PAn (black line) and mix of the two (red
line) showing three peaks of interest. Based on the ratio of the 1100, 1150 and 1728 cm−1 peaks
calibration curves were created.
placed in the vacuum oven at 50◦C for 6 hours. After the mortar cooled to room
temperature, the sample was mixed for an additional 5 minutes and at least 10
FTIR measurements were recorded.
Attenuated total reflectance (ATR) accessory with diamond crystal was used
to simplify measurements and to ensure that there was minimal deviation from
measurement to measurement. Using this technique, the depth of penetration, and
thus, the thickness of the sample, is constant, depending only on the refractive
index of the sample.
A measurement was considered satisfactory if absorbance of the highest peak
was greater than 0.4 and there was minimal or no deviation of baseline in the
water region (around 3500 cm−1). If the maximum peak was less than 0.4, the
sample was repositioned on the ATR crystal and measurements were retaken until
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satisfactory condition was met. If there was evidence of water presence in the
sample, mortar was placed in the vacuum oven for additional time until no water
was detectable by the FTIR.
For each of the 10 measurements, a sample was taken from different loca-
tion on the mortar. After the measurement was completed the maximum possible
amount of the sample was collected from the ATR crystal and returned into the
mortar, then mixed with the rest of the particles, and finaly 1-2 mg of the sample
from a different location on the mortar were taken for measurement. A set of runs
was considered successful if the deviation between the runs was less then 0.5 %. If
the deviation was greater, nanoparticles were mixed in the mortar with pestle for
additional 15 minutes and all 10 measurements were retaken until desired repro-
ducibility was met. This step was done to ensure that the small sample that was
taken to record spectra was representative of a bulk sample. After ensuring that
collected data meets set requirements, more poloxamer solution was added to the
mortar and the process was repeated until mixture ratio was 40 % poloxamer by
mass.
Based on this data calibration curves for peak pairs 1150:1100 and 1728:1100
were build, calibration curves are shown on Figure 4.5. As can be seen from
the Figure 4.5 the peak pair 1150:1100 has a greater range of peak ratio value
change for the same mass ratio range, 0.8 change for 1150:1100 versus 0.45 change
for 1728:1100, thus a better sensitivity for the mass ratio determination can be
achieved when 1150:1100 peak ratio is used, all future calculations were done
based on 1150:1100 pair of the peaks.
The procedure to analyze unknown samples was as follows: drop of the vesi-
cle suspension was placed on the ATR crystal, all water was allowed to evaporate,
then data was collected. This procedure requires that only one parameter is main-
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Figure 4.5: Calibration curves build based on the 1100:1150 and 1100:1728 peak ratios for
poloxamer - PAn mix with mass ratio of the poloxamer ranging from 1% to 40%.
tained: good contact of sample to the ATR crystal. The quality of contact between
sample and ATR crystal was monitored through the observation of the maximum
peak height value. Good reproducibility of the results was achieved when the value
for the highest peak was over 0.4. The resulted peak ratio proved to be independent
of all parameters except the mass ratio of the components if the above condition
was met and all water was removed from the sample. The peak ratio measured for
the unknown samples was compared to the calibration curve values and from the
value for the peak ratio mass ratio of the poloxamer to the PAn was determined.
To convert the mass ratio into grafting density (GD) the following equation was
derived:
GD= 200.7∗υ∗ r∗ρ÷MW
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In this equation: GD - grafting density in poloxamer chains per nm2; 200.7 -
coefficient resulted from unit conversion; υ - mass ratio of poloxamer to PAn cores
obtained from FTIR calibration curve; r - diameter of PAn cores in nm; ρ - density
of PAn cores in g/mL; MW - molecular weight of poloxamer copolymer. Equation
was derived using the assumption that PAn are perfect hard spheres that does not
form any aggregates and poloxamer chains are spread evenly on the surface of PAn.
To achieve better mass ratio resolution the core size was targeted to be close
to 30 nm, if the nanoparticles of a bigger size are used the mass of the core becomes
predominant and 1% change in the mass of poloxamer in the mixture would result
in a huge difference of GD, rendering the method ineffective. Prepared particles
were assumed to have average size of 28 nm. An assumption was made based on
the analysis of the results from three techniques: BET, SEM and DLS. According to
BET analysis, particle size is almost 28 nm. SEM imaging showed 26.9 nm. And DLS
showed 37nm average size. SEM and DLS techniques showed a relatively narrow
size distribution.
A typical image observed during SEM imaging is shown on Figure 4.6. To
calculate average size and standard deviation 200 separate, distinct cores were mea-
sured using Quartz PCI software package.
To calculate an average size of the nanoparticles based on the SEM imaging
200 distinct single nanoparticles were measured and averaged. Since besides single
nanoparticles SEM also showed formation of double, triple, quadruple and higher
aggregates fraction of each aggregate was measured. To do this, a number of every
type of aggregate was counted in 6 different areas of the sample. Based on this, a
size distribution chart was created as shown on Figure 4.7. As can be seen from the
chart, there is strong evidence that aggregates can be present in the sample after
nanoparticles were synthesized.
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Figure 4.6: Typical image observed during SEM imaging. To calculate average size and standard
deviation 200 separate distinct cores were measured.
Since preparation of the SEM sample requires the sample to be dried, there is
a probability that the observed aggregates were formed during SEM sample prepa-
ration rather than during synthesis and as such are not representative of the actual
nanoparticles that were modified. To clarify these observations, a size exclusion col-
umn chromatography was performed. Half inch wide column was filled to 4 inches
height with Bio-Gel P-100 beads, with bead’s size range 90-180 µm for wet beads.
Nanoparticles were separated according to their size using this column.
According to the SEM there is almost 15% of aggregates that consist of two
particles stuck together, and about 10% of triple and quad aggregates. If observed
on the SEM images aggregates were formed during synthesis the resulting frac-
tions from the separation column should have at least 4 different size fractions with
bigger aggregates coming out from the column first. Nanoparticles were purified
with 0.45 µm filter before loading them into the separation column. Based on the
observed size for single, dual, triple and quad aggregates these fractions were ex-
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Figure 4.7: Distribution of aggregates as observed with SEM, number average was counted.
pected to pass through 0.45 µm filter, with the quad aggregate having a maximum
size of about 100 nm. Based on the SEM observed ratio, all of these fractions
should be easily detected. To test this hypothesis 1.5 mL of particles after dialysis
were passed through the separation column. This amount is equivalent to 60 mg of
dry cores, thus there was a probability that the sample will have 9 mg of double, 6
mg of triple and 5 mg of quad aggregates. These quantities are well above detection
limit for the instrument. As can be seen from Figure 4.8 only one size was observed
exiting the column, and the results were a close match to the DLS results of the
unseparated sample.
Observed DLS results, Figure 4.8, indicate that the amount of aggregates in
the sample is much lower than was predicted by SEM, and thus particles were as-
sumed to consist of only separate single cores with an average diameter of 28 nm
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Figure 4.8: Number and intensity based average size distribution of the unmodified nanoparticles
before and after dialysis, and from the different fractions after size exclusion chromatography.
for the purpose of simplifying grafting density calculations. Most probable causes
for why such a high amount of aggregates were observed on the SEM images is
the SEM sample preparation procedure. In order to take SEM images, the sample
should be completely dry and since during drying process sample concentration in-
creases as the water is evaporated and nanoparticles are not bonded to the surface
of the SEM sample holder the probability of aggregate formation increases as the
concentration is increasing. Thus observed images appear to have more aggregates
than there are in the actual sample. Since after column chromatography only one
average size was observed, the assumption that sample does not have any aggre-
gates can be considered representative of a bulk sample.
The total surface area of the sample as measured using BrunauerEmmett-
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Teller (BET) nitrogen absorption analysis on Quantachrome instrument using Quan-
tachrome ASiQwin Automated Gas Sorption Data Acquisition and Reduction version
4.0 software package was found to be 185.7. To measure total surface area using
BET 0.3 mL of propargyl acrylate nanoparticles after dialysis were loaded into BET
tube, this volume contained 9 mg of dry cores. This tube was placed into a vac-
uum oven heated to 35◦C , at a pressure of 45 mm Hg for 72 hours to remove
all water. After this sample was degassed in the BET instrument for 10 hours at
70◦C . Normally degassing is done at the highest safe temperature for the sample
to ensure complete removal of all absorbed gasses. Glass transition temperature for
some of the acrylate based polymer can be as low as 100◦C ,thus to be below this
temperature 70◦C was chosen as a working temperature during degassing process.
It was expected that due to high cross-linking density and relatively low degassing
temperature, no changes of nanoparticle surface area will happen. Absorption of
nitrogen was done at 77.35 K and total analysis time was 1 hour 52 minutes. Based
on a multi-point BET analysis the surface area was found to be 185.7 m2/g with
correlation coefficient, R=0.999970. Report is included in the Appendix.
Since all of the three techniques used to determine real nanoparticle di-
mensions have their short comings and are not ideal when measuring polymeric
samples, few assumptions were made to calculate the size of the cores that were
prepared. Average size of nanoparticles as calculated based on the SEM images was
26.9 nm, DLS number average size for purified samples was 37 nm, BET based size
was 28 nm. SEM imaging required the samples to be dried, potentially leading to
some shrinkage and most certainly leading to significant aggregation of the parti-
cles. Additionally, the electron beam had enough power to melt propargyl acrylate
polymer while making high magnification imaging impossible due to melting. Thus
the size determined from SEM alone can not be considered to be a true size of the
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nanoparticles.
In the case of DLS measurement, to determine the real size of the nanopar-
ticles, a true refractive index for the sample has to be inputted into the instrument
software. Refractive index of the particles was assumed to be equal to the refractive
index of the propargyl acrylate polymer. Due to the presence of sodium dode-
cyl sulfate and potentially potassium per-sulfate ions that were left after emulsion
polymerization process real refractive index of the particles can be slightly different
from the pure polymer number that was used. Additionally, nanoparticles can have
a layer of bound water molecules around their surface that can lead to a higher
than actual reading by the instrument.
BET requires the sample to be completely degassed before it can be mea-
sured. This process involves high vacuum and elevated temperature that has the
potential to alter the surface area of the nanoparticles. Also BET measurement is
taken at 77 K and this can cause thermal shrinkage of the sample. Because BET re-
sults were between the SEM and DLS results and factoring in the possible influences
from all three techniques, as discussed above, the average size for the nanoparti-
cles was assumed to be 28 nm for the purposes of grafting density determination
calculations.
Derived equation for grafting density calculation combined with the devel-
oped characterization technique allows us reliable determination of the achieved
grafting density differences between various samples for the final devices using
simple and fast measurement. This tool allowed us to complete the development of
the synthesis and the purification methods required to build a nanocomposite that
if free of unattached copolymer and has fully characterized surface chemistry.
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4.2.3 Purification of the vesicles
According to Shubhra[134] findings poloxamer chains can be absorbed on
the surface of polystyrene nanoparticles at an equivalent of up to 0.2 GD and even
in a very dilute solutions number of poloxamer chains on the surface can still be
relatively high, staying above 0.1 chains per nm2 for poloxamer solutions of 0.05
mg/mL or above. Designed method of GD determination has a lower precision
limit of 1% by mass of poloxamer. Based on this lower limit and assuming perfect
sphere geometry for the PAn for 28 nm cores a lower precision limit for GD deter-
mination starts at 0.025 poloxamer chains per nm2, equivalent of 1.2 mass percent
of poloxamer. This allows to reliably differentiate between the mixes that have
the difference of 0.025 GD or more of the poloxamer which is below the expected
absorption range as reported by Shubhra.
Typical purification procedure to remove unreacted chemicals from nanopar-
ticle mixes after modifications is done via centrifugation from a suitable for impu-
rities solvent. Since equilibrium concentration of poloxamer on the surface and in
the solution are very low, poloxamer tends to stay absorbed on the surface leading
to the increase in the number of cleaning repetitions required, leading to accumu-
lation of waste chemicals that need to be disposed off. So there is a clear need in
the optimization of the cleaning procedure to remove the last few percents of the
unreacted poloxamer. Some of the common approaches to remove the impurities
from the nanoparticle suspensions include sonication followed by centrifugation,
dialysis, use of the salts to shift equilibrium states, and centrifugation at the ele-
vated temperature. All of these methods proved to be inefficient in the removal of
the last 10% of poloxamer from the vesicles.
Testing of the cleaning methods was done on a mix of PAn with stock polox-
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amer in 1 to 1 ratio. Upon first cycle of cleaning using the typical centrifugation
routine it was found that almost 12% of the poloxamer, of original 50%, was still
left in the mix. This observation matched good with what Shubhra reported be-
fore. Upon attempting to remove the remaining poloxamer it was found that all
of the typical procedures had minimal or no effect and a 10 to 12% of poloxamer
remained absorbed on the PAn. Results of the attempted cleanings are shown on
Figure 4.9.
Figure 4.9: Amount of unmodified poloxamer left in the PAn poloxamer mixture after different
cleaning routines were attempted. Ligand exchange proved to be the fastest and most efficient
method for the removal of the unreacted poloxamer.
Repetition of the centrifugation for 4 times showed no effect on the amount
of poloxamer left in the mixture. Sonication for 30 minutes also did not have the
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desired efficiency. Addition of a sodium chloride salt as well as heating proved
to have minimal effect on the equilibrium concentration and were not effective in
the removal of the last 10% of the poloxamer. Dialysis at room temperature for
17 hours also had minimal effect and only after 4 days of dialysis a decrease in
the amount of the poloxamer chains absorbed by the PAn was observed, but this
generate liters of waste, aside of taking 4 days of time. To remove the remaining
poloxamer using dialysis the time requirement would be in weeks rendering this
method economically unfeasible.
Ligand exchange procedure proved to be the most successful, and the fastest
in the removal of these last few percents of the poloxamer. As a ligand of choice,
sodium dodecyl sulfate (SDS) was used. SDS was used during the preparation of
the nanoparticles and as such it is already present at an equilibrium amounts and
addition of more SDS would just restore the original PAn surface equilibrium that
was disrupted during Click reaction.
This cleaning study allowed us to optimize the cleaning procedures after
the assembly of the nanocomposite. This knowledge proved to be of the most im-
portance for the samples with very low GD. Poloxamer modification reaction, as
described above, yields a mix of azide modified poloxamer and unmodified polox-
amer and if the unreacted poloxmaer is not removed after the Click reaction is
complete the presence of these free floating chains will result in a false GD reading.
4.2.4 Stability of the nanocomposite
Propargyl acrylate has a carbonyl bond which is susceptible to the hydrolysis
under certain conditions. Additionally, there is over 100 bonds between the surface
of the nanoparticle and end of the poloxamer that can be effected when exposed
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to higher temperatures for prolonged periods of time. To check the stability of the
proposed device PAPN was heated close to the transition temperature and changes
in the grafting density were monitored over the period of one week. Activation of
the poloxamer requires the device to be heated to relatively high temperature for
short periods of time thus knowledge about the stability of the device at tempera-
tures close to the transition temperature gives an insight on the probability of the
device destruction under normal operational conditions.
To determine the percent of the poloxamer chains that have been detached
a small portion of the sample was removed at certain time intervals and cleaned
using designed cleaning procedure (Chapter 3). Change in the poloxamer to core
ratio was monitored, the results are shown on Figure 4.10. It was found that less
than 1% of the poloxamer chains was lost per day of hydrolysis. Since for the most
treatment procedures the time needed for the vesicles to spread through the body
is just few hours the amount of the active molecules that can be lost due to high
poloxamer detachment from the vesicle is negligible and even after few days the
composition of the device is expected to be close to the original design.
4.2.5 Kinetics of Click reaction
There are two concurrent approaches to regulate the final ratio of the com-
ponents in a composite. First is to dose the feeding ratio for the chemical reaction
and let the reaction run to a completion. Second option is to add the excess of one
of the components, typically molecule that is used to create the shell, in this work
azide modified poloxamer, and to stop the reaction after some distinct period of
time, usually minutes to hours. In the first case there is no waste of the compo-
nents and typically the cleaning of the final composite is not required, but the time
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Figure 4.10: Change in poloxamer grafting density of the PAPN after being exposed to 50 ◦C
temperature for one week.
required for the reaction to complete can be days if not weeks, so this approach
is more suitable for expensive components and when post reaction purification is
complicated. Second approach allows to speed up the process, but requires an ad-
ditional step to remove the excess of the reactants. This is more suitable for the
processes where post purification is simple and efficient, and starting compounds
that are used in excess are cheap. Also second approach requires a knowledge about
the kinetics of the reaction to determine when to stop the reaction.
To measure the rate of poloxamer attachment reaction was loaded with 5
times excess of the poloxamer and samples were taken at 1, 3, 6, 24, 48, 96 and
168 hour after the start of the reaction, results are shown on Figure 4.11. A clear
surface saturation around 0.55 poloxamer chains per nm2 of the surface after 96
hours of reaction is observed. Based on this data an estimation of the required time
to achieve the desired grafting density level can be made.
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Figure 4.11: Dependence of the achieved GD of the poloxamer on the time of the reaction. 5 times
excess of azide modified poloxamer was added into the reaction and samples were taken, cleaned
and analyzed at 1, 3, 6, 24, 48, 96 and 168 hour.
4.2.6 Numerical estimation of grafting density influence
Numerical estimation of grafting density influence on the shell properties
were made to check if the shell that is created by the poloxamer has enough vol-
ume to accommodate encapsulation of the dyes or drugs at a level that can have
a practical application. Theoretical dimensions of the modified nanoparticles were
calculated based on available literature data. Length and dimension of ethylene ox-
ide (EO) and propylene oxide (PO) blocks were calculated based on the literature
values for characteristic values of polyethylene oxide (CN 4.1) and polypropylene
oxide (CN 4.85) polymers[135]. Following assumptions were made: expansion
factor for polymer chains is equal to 1; poloxamer copolymer is a perfect mono-
disperse polymer with each ethylene oxide block consisting of 12 repeat units and
propylene oxide block consisting of 32 repeat units. Average bond length for the
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repeat unit was found as a mathematical average between typical theoretical O-C,
C-C and C-O bond lengths (0.143, 0.154 and 0.143 respectively, average 0.1466
nm was used). End to end distance for EO block at theta conditions was calculated
to be 1.78 nm, calculated using the following equation[135]:
〈r2〉 12 = α(nCN) 12 l
PO block was assumed to be in a blob conformation and as such radius of
gyration (Rg) at theta conditions was calculated to be 1.25 nm, calculated using the
following equation[135]:
Rg =
〈r2〉 12√
6
Theta conditions are characterized by a more compact conformation for poly-
mer chains than in the good solvent. Based on this fact calculated dimensions for
EO and PO as described above were assumed to be equal to the height of the shell
when heated above LCST. As was shown in Chapter 3 the distance between two
dyes changes by almost 1 nm when described device is heated from room tempera-
ture to above LCST. Based on this data the assumption that poloxamer shell height
increases by 1 nm when heated above LCST was made as compared to the theta
conditions state.
Using basic geometrical calculations for the volume of a sphere (V = 43pir
3)
the total volume for two states was found: collapsed shell - V = 140800nm3, ex-
panded shell - V = 154300nm3. As a radius for the collapsed state of the shell sum of
core radius, the end to end distance for EO block and the diameter (twice the radius
of gyration) of the PO block was found (28 + 1.78 + 2 * 1.25 = 32.28 nm), for
expanded state 1 nm was added based on the results obtained in Chapter 3. The dif-
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ference between these two volume is the expansion of the shell thus change in shell
volume due to the temperature triggered collapse is estimated to be 13500 nm3 for
the 2400 nm2 of the single nanoparticle surface. Calculated volume is sufficient to
accommodate hundreds or even thousands of molecules, since molar volume for
most of the dyes and small molecule drugs is less than 1 nm3, as predicted by the
ACD/Labs 12.0 ChemSketch software package, thus the proposed system has the
potential to be used as a drug delivery device.
When making the calculations of the total radius of the device conformation
of the poloxamer on the surface was assumed to be as shown on Figure 4.12, sec-
ond, upper layer of EO was not included in the total length calculations because
based on the literature review it is expected that dyes or drugs would be encapsu-
lated in the PO block leaving the EO block the function of protection layer rather
than active layer.
4.2.7 Numerical prediction of optimal grafting density
Polymer chains that form brushes on the surface of the nanoparticle will form
various structures based on the grafting density and at certain conditions it is pre-
dicted that chains will be restricted in their ability to change conformation when
going through phase transition processes[136]. To find if the poloxamer chains
have the optimal grafting density that will results in the maximum volume change
for the shell, the length of tethered chains for good solvent and theta solvent con-
ditions were calculated. Calculations were based on the Van Der Waals volume
for repeating unit and the dependence of the flexible polymer chain length on the
solvent[137].
Van Der Waals volume for repeating units were found on polymerdatabase.com
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Figure 4.12: Cartoon showing assumed conformation of the poloxamer covered nanoparticles
with calculated dimensions of the blocks. Ethylene oxide block is shown in green, propylene oxide
block is shown in red.
website: Poly(ethylene glycol) has volume of 26.4 cm3/mol, Poly(propylene glycol)
has volume of 36.4 cm3/mol. This website provides Van der Waals volumes that
have been calculated from the bond lengths and the atomic radii of the elements.
This approximation is expected to be good enough to demonstrate the expected
behavior as the grafting density of the poloxamer approaches critical density and
steric effects start to govern the conformation of the chains.
The average molar volume of the repeat unit for poloxamer was found ac-
cording to the molar fractions of EO and PO blocks in the copolymer. Molar fraction
of EO block equals to (12 + 12) / (12 + 32 + 12) = 0.42857, molar fraction of PO
block equals to 1 - 0.42857 = 0.57143. Based on this average repeat unit volume
is 26.4 * 0.42857 + 36.4 * 0.57143 = 32.1143 cm3/mol or 0.0533 nm3/unit. To
simplify the calculations brush thickness was considered to be equal to the length of
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the polymer chain in good solvent for temperature below LCST and to the length of
polymer chain in theta solvent for condition when the temperature is above LCST.
The relationships between dimensions of polymer chain and grafting density
were calculated using equations for good solvent and theta solvent as reported by
Flory[137]. Equation for good solvent[137]:
L= N(a/d)
2
3a
where L is the length of the polymer chain, thickness of the brush was assumed to
be equal to this length; N is number of repeat units in the polymer chain, number of
repeat units was added for all three blocks (56 total for Pluronic-L64); a is volume
of one repeat unit, found as described above; d is the distance between poloxamer
chains on the surface, this was the parameter that was varied to build the graph (x-
axle on Figure 4.13. To calculate brush thickness at theta conditions the following
equation was used[137]:
L= N(a/d)a
Difference between theta and good solvent (y-axle) was plotted to demon-
strate the maximum volume change when triggered with temperature for polox-
amer copolymers, shown on Figure 4.13.
Using calculated shell thicknesses as predicted by the theory on the confor-
mation of the flexible polymer chains in solution[138, 136] a maximum for the
volume change between the theta and good solvent conditions was found, shown
on Figure 4.13. Based on this prediction it is expected that for proposed system
an optimal grafting density exists that will lead to the maximum release rate due
to maximum volume change of the shell that will be triggered by the maximum
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Figure 4.13: Dependence of poloxamer brush thickness on grafting density.
change in the brush height.
Obtained numbers are only approximation since a lot of assumptions and
approximations had to be made during calculations and that is probably why the
observed calculated maximum is at the chains separation distance of just 0.2 nm,
making grafting density much higher than the possible maximum grafting density
as found during kinetics of click reaction study section.
4.3 Conclusion.
Proposed is a method of synthesis and characterization of a well defined
nanocomposite from propargyl acrylate and poloxamer. The proposed nanocompos-
ite has a better stability compared to the self assembled devices and a wider range of
temperature tuning compared to the PNIPAM based core shell systems. A quantita-
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tive method based on FTIR was designed to simplify the process of nanocomposite
characterization. This method allowed us to quickly and reliably determine the
composition of the nanocomposite. The ability to choose from a wide range of the
commercially available poloxamers and the ability to synthesize PAn with a wide
range of the core sizes allowed us to create a device with a desired shell density.
Poloxamer copolymer, the temperature responsive component, allows us to tune the
response of the device to the desired temperature range simply through the selec-
tion of a correct copolymer version. Stability of the nanocomposite was tested and
determined to be sufficient for medical applications conditions. Based on the prop-
erties of the components optimal method for purification of the final nanocomposite
was described. This method allowed us to remove all of the unattached poloxamer
from the device in a few easy steps.
4.4 Experimental methods
4.4.1 Materials and Reagents
All reagents were purchased from Sigma-Aldrich with at least 97% purity
level, solvents were purified using standard procedures. Deionized water was ob-
tain from Barnstead Nanopure Diamond water system and had 18.2 MOhm resis-
tance.
4.4.2 Characterization
1H spectra were recorded on JEOL ECX-300 spectrometers (300MHz for
proton). Chemical shifts for protons are reported in parts per million downfield
from tetramethylsilane and are referenced to the carbon resonances of the solvent
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(CDCl3: δ 7.26 or DMSO-d6: δ 2.50). Nanoparticle size was checked using Malvern
Instruments Zetasizer nano series Nano-ZS using 10 mm plastic cuvette. Addition-
ally, average size was confirmed using scanning electron microscope Hitachi S4800
FESEM at maximum accelerating voltage of 20.0 kV, images were analyzed us-
ing Quartz PCI v.8.5 software package. BET analysis was done on Quantachrome
Instrument and analyzed using Quantachrome ASiQwin- Automated Gas Sorption
Data Acquisition and Reduction software package version 4.0. FTIR was done on
a Nickolet Magna IR 6700 spectrometer equipped with a diamond attenuated total
reflectance (ATR) accessory.
4.4.3 Nanoparticle preparation
Emulsion polymerization was performed in a single necked round bottom
flask (250 mL) equipped with the magnetic stirrer. Potassium persulfate (110 mg)
was dissolved in water (80 mL) and nitrogen was purged through the solution
for 15 minutes. Sodium dodecyl sulfate (90 mg) was added to the flask under
nitrogen purge. Obtained solution was stirred and placed in the preheated bath
at 75 ◦C for 3 minutes, then degassed solution of propargyl acrylate (4 mL) and
divinylbenzene (0.65 mL) were added to the main reaction flask. The mixture was
stirred at 75 ◦C under nitrogen purge for 90 minutes. The emulsion was allowed to
cool on air. Then mixture was filtered through paper filter. After filtering samples
were purified by dialysis using Spectra/Por Dialysis membrane with MWCO 50000.
Dialysis was performed for 3 days at 40 ◦C in 18.2 Megaohms water with regular
water changes, typically every 8 hours. Nanoparticles were characterized using
DLS,SEM and BET analysis to determine average size and aggregation. Average size
of the nanoparticles, based on the analysis from all three techniques, was assumed
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to be 28 nm. Obtained emulsion contained 45 mg/mL of nanoparticles.
4.4.4 Poloxamer modification
MeSO2-pluronic-L64. Pluronic-L64 (3.14 g, 1.064 mmol) was dissolved in
dry dichloromethane (DCM) (10 mL), then triethylamine (0.132 g, 1.3 mmol) was
added to the solution. The obtained solution was stirred at room temperature.
Methanesulfonyl chloride (48 mg, 0.42 mmol) was dissolved in 0.5 mL of dry DCM
and obtained solution was added drop-wise to the poloxamer solution over 1 minute
period of time. The mixture was stirred for 6 hours at room temperature. 20 mL
of deionized water was added to remove any unreacted methanesulfonyl chloride.
Mixture was transferred to separation funnel and mixed for 2 minutes. Then sepa-
ration funnel was positioned vertically and mixture was allowed to phase separate.
If phase separation was not observed for more than 5 minutes 10 mg of sodium
chloride was added, mixture was shaked again for 3 minutes and again allowed to
phase separate. Bottom, organic, layer was collected and transferred in clean sep-
aration funnel. 20 mL of deionized water were added and mixture was shaked for
3 minutes again. After shaking mixture was allowed to phase separate and organic
layer was collected from the bottom of the separation funnel. 5 g of sodium sulfate
was added to remove remaining water from the mixture. After 5 minutes the mix-
ture was filtered and evaporated under reduced pressure. Yield 3.1 g (95%), clear
oil. This product was used in the next step without further purification. 1H NMR
(CDCl3) δ 1.11 (m, 96H), 3.06 (s, 3H), 3.38 (m, 32H), 3.52 (m, 64H), 3.63 (m,
98H).
Reduced amount of methanesulfonyl loading was chosen to decrease the
probability of dual end azide modified poloxamer formation at the end of the mod-
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ification process. Separation of the single and dual end azide modified poloxamers
would be a very challenging task and because the price for the poloxamer is rela-
tively low it is more rational to starve the reaction and have some umodified polox-
amer left at the end of the modification process, rather than spending time and
reagents in an attempt to separate the single and dual end modified poloxamers.
Unmodified poloxamer can be easily removed after Click reaction because it does
not have azide group, thus it cannot react with the alkyne group on the surface.
Assuming equal rate of reactions for umodified poloxamer and single end
modified poloxamer the probability of formation of dual end modified poloxamer
at the proposed loading is close to 3.5 % according to statistical probability calcula-
tions, while probability of single end modified poloxamer is 33 %.
Probability of dual end modified poloxamer was calculated using the fol-
lowing assumption: there is no difference between end hydroxyl groups on either
of the versions of poloxamer and the probability of any of the hydroxyl group re-
acting with methanesulfonyl chloride is equal. The initial state of the system was
calculated based on the loading ratios, following numbers were used: there was a
total of 100 unmodified poloxamer chains available, that have a total of 200 end
hydroxyl groups; there was a total of 40 methanesulfonyl chloride molecules. This
ratio was calculated based on the molar loading ratio that was used during first step
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of poloxamer modification.
Each reaction step one methanesulfonyl group was reacting with any of the
available hydroxyl groups. The total number of possible events was found as 200
* 40 for the initial state of the system. After consuming the first methanesulfonyl
group only possible product was first single end modified poloxamer chain, making
new state of the system with the following parameters: 99 unmodified poloxamer
chains bearing 198 end hydroxyl groups available for reaction, 1 single end modi-
fied poloxamer with 1 group available for reaction and 39 remaining methanesul-
fonyl chloride molecules. New total number of possible reactions: 198 * 39 + 1 *
39 after first step.
Probability of single end modified chain reacting during next step was found
as the number of possible events for single end modified chains participating in the
reaction divided by the total possible number of hydroxyl group reacting with any
of methanesulfonyl group: 1 * 39 / (198 * 39 + 1 * 39). Probability of unmodified
chains participating in the reaction was found based on the number of available
end hydroxyl groups left after first step: 198 * 39 * /(198 * 39 + 1 * 39). This
process was repeated until all 40 methanesulfonyl chloride molecules were con-
sumed. Based on these calculations the resulting number of chains in the mix, after
all methanesulfonyl chloride was consumed, was: 63.49% of unreacted, 33.02%
single end modified and 3.49 of dual end modified chains. Table with calculations
is included in the Appendix section.
Pluronic-L64-N3. Sodium azide (195 mg, 3 mmol) was added into solution
of MeSO2-pluronic-L64 (3.1 g, 1.03 mmol) in dimethylformamide (DMF) (10 mL).
The mixture was stirred and heated to 80 ◦C for 3 hours. After cooling the mixture
was extracted with DCM and washed with water 2 times as described in the first
step of the poloxamer modification. The organic layer was separated, dried with
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Na2SO4, filtered and evaporated under reduced pressure. Yield 2.27 g (75%), clear
oil. Pluronic-L64-N3 was used in the next step without further purification. 1H
NMR (CDCl3) δ 1.07 (m, 96H), 3.34 (m, 32H), 3.48 (m, 64H), 3.59 (m, 98H).
4.4.5 Nanoparticle modification
Nanoparticle modification was performed using the azide alkyne Huisgen
cycloaddition reaction also known as Click chemistry. Typical procedure was used
as described elsewhere [41]. Copper(II) sulfate (CuSO4) (2 mg, 8 µmol) was added
to the propargyl acrylate nanoparticles suspension in water (2 mL) and stirred until
completely dissolved. Then solution of pluronic-L64-N3 (6) (22 mg, 7 µmol) in
water (2 mL) was added. Next the solution of CuSO4 (2 mg, 8 µmol) in water (2
mL) was added. The reaction was stirred and purged with nitrogen for 5 minutes,
then sodium ascorbate (10 mg, 50.5 µmol) was added. The reaction continued
at 28◦C for 24 hours under nitrogen purge. Reaction mixture was centrifuged at
10000G for 10 minutes. Separated nanoparticles were washed with the mixture
of water:Methanol 1:1 (20 mL). Then 1 mL of 0.1 M ethylenediaminetetraacetic
acid (EDTA) solution was added to remove copper catalyst. Nanoparticles were re-
dispersed in 40 mL of 18.2 Megaohms water and sonicated for 3 minutes. After
sonication suspension was centrifuged at 10000G for 10 minutes. This step was
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repeated 2 times. Next 0.1 mL of 20% sodium dodecyl sulfate (SDS) solution was
added to remove any unreacted poloxamer. Nanoparticles were re-dispersed in
40 mL of 18.2 Megaohms water and sonicated for 3 minutes. After sonication
suspension was centrifuged at 10000G for 10 minutes. This step was also repeated
twice. Lastly nanoparticles were re-dispersed in 40 mL of 18.2 Megaohms water and
sonicated for 3 minutes. After sonication suspension was centrifuged at 10000G for
10 minutes. This step was repeated 5 times to ensure that all impurities were
removed. After last centrifugation nanoparticles were redispersed in 10 mL of 18.2
Megaohms water and stored in the refrigerator.
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Chapter 5
Dependence of encapsulation and
release efficiency of propargyl
acrylate poloxamer nanocomposite
on the grafting density of poloxamer
Recently developed drug delivery vesicles act as promising next generation
disease treatment devices. However, the majority of these vesicles are synthesized
using complex synthesis routes, or in the case of self-assembly vesicles, lack stability
in the human body environment. Here, an original propargyl acrylate (PA) - polox-
amer composite vesicle capable of encapsulating and releasing active molecules in
a controlled way is described. This is the first demonstration of the poloxamer
grafting density (GD) influence on the release efficiency from the PA - poloxamer
nanoparticle composite. Control over the poloxamer grafting density on the PA sur-
face allows us to program the drug release speed of the vesicles. Optimization of
GD allowed us to increase the release rate of active molecules by up to 63 times
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when compared to the unmodified PA nanoparticles. This burst release is temper-
ature sensitive, and through the combination of various versions of the poloxamer
copolymer, it is expected that the temperature of the fastest release can be tuned
to the desired temperature region allowing programing of the treatment plan based
on the specific needs.
5.1 Introduction
With the current advances in disease treatment technologies, there is a push
towards a targeted drug delivery [113, 139]. A lot of current research efforts are
aimed at creating a system that is capable of multitasking: specifically bind to a
target cells; enhance visibility of the target cells through the use of a photo- or
radio-luminescent markers; and deliver active drugs while minimizing damage to
the healthy cells [140]. One of the approaches to achieve the above goals is to
encapsulate the active molecules in a vesicle that can be activated by an external
or internal trigger when the device reaches its target [141]. A system that can be
used for a multitude of active molecules must meet the following criteria: should
be bio-compatible; capable of encapsulating a wide range of active molecules; pro-
vide adequate protection for these molecules from the human body environment;
prevent activation of the active molecules before they reach the target cell; have a
targeting route to ensure the accumulation at the cite of interest; and have a reliable
activation mechanism.
Core-shell structured vesicles that use graft to method to attach an active
corona to the core are among the most promising systems currently being devel-
oped [142]. The main benefit of such systems is the stability of the formed vesicle
due to the formation of a chemical bond between the core and the corona. Most
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of the time, as a temperature responsive component, poly(N-isopropylacrylamide)
(PNIPAM) derivatives are used [143, 144]. A major challenge of such systems is the
complex synthesis routes and more importantly PNIPAM temperature of response
is locked at 32◦C. To change this temperature PNIPAM, has to be co-polymerized
with other polymers increasing the complexity of the synthesis [145]. An alterna-
tive approach is based on the use of the self-assembly of temperature responsive
polymers [146]. Such systems benefit from much simpler synthesis and the pos-
sibility to control the temperature of response [31]. One of the challenges of the
self-assembled systems is their instability due to the nature of the bond between
components and most of the self-assembly systems lack the control over the size of
the final device, limiting their application range [147, 19]. Ability to control the size
of the drug delivery vesicle for cancer therapy is crucial because it allows the use of
a passive targeting to achieve the accumulation of the vesicles in the cancer tissues.
Cancer tissue is known to have a higher porosity of the blood vessels compared to a
normal tissue and vesicles within the 40 to 200 nm size range were shown to specif-
ically accumulate in the cancer tissue just due to the higher penetration capability
of the blood vessels [125, 103, 104].
To address the issue of the complex synthesis and to retain ability of the pre-
cise control over the size of the final device while maintaining high stability of this
device in different environments, a system build around propargyl acrylate (PA)
nanoparticle core decorated with the poloxamer corona is proposed. PA nanopar-
ticles have been proven to be bio-compatible and effective when used for medical
applications [40]. The PA surface can be modified through Click chemistry [148]
eliminating the need for expensive or aggressive solvents or catalysts and can be
done in a one pot, one step reaction. PA nanoparticles can also be prepared in a
wide range of sizes.
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Temperature control is achieved through the use of the poloxamer family of
copolymers. A corona composed of the poloxamer offers the possibility to control
the temperature of response simply through the change in the poloxamer compo-
sition [31]. Additional benefits of the poloxamers include: improved stability of
the active molecules trapped inside of the poloxamer matrix [88, 96]; ability to
re-sensitize the cancer cells to the drugs [98]; hydroxyl groups on the ends of the
copolymer can be substituted with the azide group to simplify the assembly of the
device through the use of Click chemistry; and the poloxamer has been shown to
prolong the lifetime of the vesicles surrounded by it in the blood stream environ-
ment [149, 32], increasing the time requirement until the next drug administration
event.
A multitude of properties of the drug delivery vesicles are important when
designing an optimal treatment plan. For situations where there is a need to main-
tain a certain level of the active molecules in the blood stream for extended periods
of time, there is a need for a system that is capable of slowly releasing the encapsu-
lated molecules over long periods of time. When there is a need to locally increase
the concentration of the drug at the site of interest, there is a need for a system
that can burst release high concentrations of the active molecules when triggered.
In this work, we demonstrate that grafting density (GD) can be used to program
the release efficiency of the device. This allows the design of a drug delivery device
with the highest possible effectiveness for the intended application.
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5.2 Results and Discussions
5.2.1 Nanocomposite preparation
To build a programmable drug delivery vesicle, a versatile emulsion poly-
merization of PA was used. This allowed us to synthesize a nanoparticle with a
28 nm core size, as measured with the BET analysis. PA core was covered with
a temperature sensitive poloxamer copolymer with a 2950 molecular weight that
consisted of 32 propylene oxide units in the center block and 12 ethylene oxide
units in each end block. To attach the poloxamer to the surface of the nanoparti-
cle, one of the hydroxyl groups on the end of the copolymer was substituted with
the azide group and then a set of devices with a wide range of poloxamer grafting
densities was prepared and characterized using Fourier Transform Infrared (FTIR)
spectroscopy and Scanning Electron Microscopy (SEM) techniques as described in
previous chapter. To test the encapsulation and release efficiency, Rhodamine B dye
was used as a model drug. General scheme of the device and suggested positioning
of the dye is shown on Figure 5.1A.
To estimate the range of the grafting densities for the samples that have to
be prepared, a theoretically fully covered with poloxamer PA core was calculated.
Calculations were based on the characteristic ratios of ethylene oxide and propylene
oxide polymer, based on literature values as described in Chapter 4. Radius of the
propylene oxide block was assumed to be equal to the radius of gyration (Rg) of the
propylene oxide (PPO) polymer of the same length and was calculated using the
following equation, an assumption that PPO is in the blob conformation was made
and all calculations were done for Theta conditions[105]:
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Rg= 0.41∗α∗ (nb∗Cn)0.5 ∗ l
In this equation α is the chain expansion factor (for theta conditions α is
equal to 1); n is number of bonds (for PPO block in the poloxamer used this number
is 96, PPO block contains 32 propylene oxide repeat units); Cn is characteristic ratio
(tabulated value was found in literature[105]); l is bond length (tabulated value
was found in literature[105]).
To determine the length of the ethylene oxide (PEO) block the end to end
distance (< r2 >0.5) was estimated using the following equation[105]:
< r2 >0.5= α∗ (n∗Cn)0.5 ∗ l
In this equation n is number of bonds (for PEO block in the poloxamer used
this number is 36, it consists of 12 ethylene oxide repeat units on each end).
The following assumptions were made during the calculations of the the-
oretical fully covered with poloxamer PA nanoparticle: perfectly spherical shapes
for the nanoparticles and PPO blobs; no overlapping of the poloxamer chains, and
square positioning of the PPO blobs in the space around the nanoparticle surface.
Based on the calculated values for Rg, < r2 >0.5 and the assumptions made the fully
covered GD was calculated to be 0.25 poloxamer molecules per nm2. This value
is in agreement with the results obtained in Chapter 4 and is roughly half of the
maximum GD that was achieved experimentally.
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Figure 5.1: Scheme of the grab and release mechanism for the proposed system. A Device is below
LCST of the poloxamer. Poloxamer chains are in their expanded state. This creates ample space for
the dye to fit in. B Device is heated above LCST of the poloxamer. Poloxamer chains are in their
collapsed state. Free volume inside of the shell is not sufficient enough to hold the dye any longer,
the dye is released into solution.
5.2.2 Temperature triggered burst release
As a possible mechanism of the burst release, the following process is sug-
gested. When vesicles were heated above the lower critical solution temperature
(LCST) of the poloxamer used, the corona collapsed, triggering the release of the
dye. Schematically this state is shown on Figure 5.1B. Poloxamer chains form hy-
drophobic pockets [31] that form the corona around the PA core. This corona acts
like a ”sponge” with internal spring mechanism that can be activated at a specific
temperature. At temperatures below LCST, poloxamer chains are in their relaxed
state, the spring is expanded, and offer ample volume for the dye to fit in. Be-
low LCST the ”sponge” is in its swelled state. When the vesicle is heated above
LCST, the packing of the poloxamer chains densifies [31], the springs contracts,
decreasing the free volume, while squeezing the ”sponge”, forcing the dye in to the
solution.
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To achieve the ability to program the release rate of the device GD influence
on the release dynamics at various temperatures was investigated. As was shown in
Chapter 4, theory predicts that there should exist a grafting density that will result
in the maximum volume change of the shell. Thus it was expected that a maximum
burst release rate can be observed. Rhodamine B was used as a model drug due to
its well defined absorption characteristics and the ease of its concentration deter-
mination. The dependence of the release rate of Rhodamine B on the temperature
and GD is shown on Figure 5.2. As can be seen on Figure 5.2, the increase in the
dye release rate with the temperature is dependent on the GD of the poloxamer
and demonstrates a clear optimal GD when the maximum release rate is reached,
confirming theory based calculations. This knowledge allows us to design a device
with a defined release efficiency to optimize the treatment plan for each individual
case and to achieve the fastest remission while decreasing the side effects from the
treatment.
Unmodified PA cores have no temperature responsive components and, as
such, have a very limited increase in the release rate with the increase in the tem-
perature. This can be mostly attributed to the increased mobility of the dye at a
higher temperatures, resulting in the shift of the equilibrium states between the ab-
sorbed and free dye, represented by a zero grafting density data point on Figure 5.2.
With the introduction of the poloxamer, a temperature responsive component is in-
cluded in to the system, making burst release a possibility due to the changes in
the poloxamer chain conformation. Rearrangement of the poloxamer chains when
heated above LCST of the poloxamer causes the reduction of the shell’s free volume
pushing anything trapped inside of the shell to the outside edge of the vesicle, and
eventually leading to a complete release of the dye from the device volume and in
to the solution.
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Figure 5.2: Rate of Rhodamine B release from vesicles with different GDs below and above LCST
of the poloxamer used. Unmodified nanoparticles showed the best retention and almost no release.
Vesicles with poloxamer shell showed initial increase in release capabilities with increase in GD, but
after reaching GD of 0.35, poloxamer chains per nm2 release effectiveness started to decrease until
it almost completely lost the temperature triggering capability.
Observed differences in the dye release are most likely the result of a combi-
nation of two factors: positioning of the dye in the vesicle, governed by the ability
of poloxamer to form hydrophobic pockets [31] (schematically positioning of the
dye in the vesicle is shown on Figure 5.1A); and the change in the dimensions of
these pockets with the temperature, governed by the changes of the poloxamer coil
packing (the two states are schematically shown on the Figure 5.1A and B).
Using Fo¨rster Resonance Energy Transfer theory, as described in Chapter 3,
and based on the calculations in Chapter 4, the extent of the poloxamer corona
dimensions change was found to be on the order of 1 nm when the device is heated
from 20◦C to 60◦C. This change of the dimensions of the corona is proposed as the
98
main mechanism behind the release mechanics of the device. The change of the
poloxamer coil dimension causes the release of the dye: poloxamer goes from the
expanded sponge like state to a squeezed sponge state, releasing its cargo.
At a very low grafting density, Figure 5.3A, the percent of the dye that is lo-
cated inside of the poloxamer pocket is small. Thus, upon temperature triggering,
only the part of the dye that is encapsulated in the poloxamer pockets is burst re-
leased, as shown by the first three data points on Figure 5.2, and the rest of the dye
is released through the same mechanisms as in the case of the unmodified nanopar-
ticles which is much slower and depends only on the concentration gradient.
At the optimal GD, Figure 5.3B, all of the surface of the PA core is covered
with the poloxamer, preventing the dye from sticking to the surface. At this GD,
there is plenty of volume for the poloxamer chains to accept any conformation.
This allows the chains to arrange themselves according to the lowest energy state
configuration. Upon heating above LCST, a complete rearrangement of the polox-
amer chains is happening. This rearrangement causes the release of the dye at a
much higher rate than the rate of any other samples, as shown by the peak on
Figure 5.2. There is almost a 16 times increase in the release rate for the same GD
sample when heated from room temperature to above LCST (poloxamer used in this
study has LCST of 58◦C) and 63 times increase in the release rate when compared
to the unmodified nanoparticles at room temperature.
It is possible to increase the grafting density past this optimal value through
the increase in the reaction feed ratio and the reaction times [150]. Increasing the
GD past the optimal point causes the decrease of the free volume in the corona
and, thus, limits the ability of the chains to alter their coil dimensions with temper-
ature due to steric effects. This leads to a decrease in the burst release efficiency.
Schematically, this packing state is shown on Figure 5.3C. At this packing state, coils
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are packed too densely and their ability to change the coil dimensions is partially
restricted by the steric hindrance, decreasing the rate of the dye release. Volume
around the PA core is limited by the dimensions of the core and length of the copoly-
mer. Thus, at high GD, the majority of this volume is occupied by the poloxamer
coils instead of being available for the dye.
Figure 5.3: Schematic representation of the surface morphology based on the grafting density.
A. GD is low and a significant surface area is open, allowing the load to stick to the surface rather
than being trapped inside of the poloxamer pockets. B. GD is optimal, all surface is covered with
poloxamer chains, all load is encapsulated inside of the poloxamer pockets. C. GD is too high, chain
movement is restricted by the neighboring chains, release rate is decreased compared to optimal
GD.
The ability to design a system with the capability to burst release large quan-
tities of active molecules when triggered with temperature can facilitate the creation
of a smart drug delivery vesicle for the cancer treatment application. Poloxamers
are commercially available in the wide range of the response temperatures, allowing
us to match the temperature to the required application. As one of the examples of
such temperature ranges, cancer tissue elevated temperature can be targeted. Can-
cer tissue was shown to have a higher temperature [19] compared to the rest of the
body and this difference can be used to trigger the burst release of the anticancer
drugs in the cancer tissue while maintaining a safe concentration of the drug in the
rest of the body.
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5.2.3 Encapsulation efficiency
To compare encapsulation efficiency of PAPN with different grafting densities
an equivalent of 20 mg of dry cores was loaded into the dialysis bag with a 12000
Dalton molecular weight cutoff. Float-A-Lyzer G2 dialysis membranes were used
for this study, since they offer an easy to load solution with the screw on cap and
come assembled and ready to use, pre-cut to the same dimensions. Each sample
was brought to a total volume of 5.5 mL and 2 mg of Rhodamine B dye was added
(equivalent of 0.675 Rhodamine B molecule per nm2 of the surface). This amount of
the dye was experimentally determined to be just over the limit of the encapsulation
capacity for the unmodified nanoparticles. Then each dialysis bag was loaded in to
a 50 mL centrifuge tube and 37 mL of deionized water was added to the tube.
Two centrifuge tube holders were glued together to allow loading of 8 cen-
trifuge tubes at the same time. This assembly of two holders was attached to the
horizontal shaft of the electric motor with rotation speed control. Centrifuge tubes
were fixed inside of the holders, ensuring that they will not fall out when the holder
is rotated upside down. Speed of rotation was set to approximately 1 revolution ev-
ery 5 seconds. This speed was found to be efficient enough to ensure good mixing
of the sample while remaining slow enough to prevent the possibility of the dialysis
membrane rupturing. Whole assembly was placed in the cardboard box lined with
aluminum foil on both sides, leaving the electrical motor outside of the box. Box
dimensions were selected to allow free rotation of the holder inside of it, leaving
ample space for the heating plate at the bottom. The heating plate was positioned
at the bottom of the box centered under the samples and a temperature sensor
was attached to the top of the box hanging down 2 inches, touching the top of the
centrifuge tubes. The box was sealed with aluminum foil to create an oven like
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environment.
For the room temperature encapsulation or release measurements, no heat
was used, just rotation. For the burst release above LCST of the poloxamer, box
temperature was set to 65◦C . The 7 degree increase over LCST of poloxamer was
chosen to ensure that the samples will be heated over LCST. Positioning of the sen-
sor was at the top of the box, creating a possibility that the actual sample temper-
ature can be slightly different from the sensor readouts. Thus this extra 7 degrees
were added to compensate for the setup deficiencies.
Figure 5.4 shows the dependence of the encapsulation capacity on the graft-
ing density. Unmodified nanoparticles, the sample with GD of 0, showed the best
encapsulation capability and their effectiveness was used as a normalization refer-
ence for the rest of the samples. Measurements of encapsulation efficiency were
done based on the difference between the loaded amount of the Rhodamine B and
the amount of Rhodamine B dye that was detected in the supernatant solution after
2 hours of dialysis. Water in the centrifuge tubes was changed every two hours and
the content of Rhodamine B dye in the supernatant was measured. To measure the
dye content in the supernatant solution the UV/Vis spectra was recorded and ab-
sorbance of each sample was compared to the previously recorded calibration curve
for the known Rhodamine B concentrations. To obtain total mass of the Rhodamine
B dye that was released, measured concentration was multiplied by the total vol-
ume of the supernatant solution (37 mL). This total mass was subtracted from the
2 mg that were initially loaded, to obtain the encapsulation efficiency number.
It was established, that at a very low GD, there was only a slight change
in the encapsulation efficiency of the vesicles compared to the unmodified cores,
as shown by the second data point on Figure 5.4. As the grafting density was in-
creased, encapsulation efficiency quickly dropped to about 80% of the unmodified
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Figure 5.4: Encapsulation effectiveness of vesicles with various GDs in the first 2 hours. Un-
modified nanoparticles were capable of holding close to 1 Rhodamine B molecule per 3 nm2 of the
surface, while modified nanoparticles were able to retain about 80% of this efficiency.
nanoparticles and remained mostly independent of the grafting density there after,
as shown by the 3rd data point and to the end of the graph on Figure 5.4. We sug-
gest that this is caused by the balancing of the two volumes that are available for the
dye to go in to: first is the volume formed by the propargyl groups on the surface of
the cores and the second volume is formed by the hydrophobic pockets of the polox-
amer chains. Even though the total volume that is formed by the poloxamer chains
is greater than the volume formed by a single layer of propargyl groups on the sur-
face, majority of this poloxamer formed volume (the shell around the PA core) is
filled by the co-polymer itself, and only the voids between copolymer chains are
accessible for the dye. This finding shows that there is no significant dependence in
the encapsulation ability of the vesicles based on the grafting density, and from the
retention point of view, there is no significant difference between different grafting
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density samples. This finding suggests why in all the literature that was reviewed,
no studies related to the grafting density influence on the encapsulation capacity
was reported.
5.2.4 Extended release
High encapsulation efficiency alone is not enough to make an effective ex-
tended release delivery vesicle. Second and more important property needed, is a
well defined release profile over the extended periods of time. All 7 samples were
loaded in the dialysis bags and were placed in a 50 mL centrifuge tubes, then 37 mL
of deionized water was added to each tube. Next samples were placed on a rotating
mixer to provide sufficient mixing to simulate the dilute environment of a human
body. The change in the release rate was determined based on the increase of the
Rhodamine B content in the dialysate water as measured by UV/Vis and calculated
using Beer-Lambert law, results are shown on Figure 5.5.
The observed initial big decrease in the release rate was due to intentional
overloading of the vesicles with the dye to ensure that the maximum possible en-
capsulation was reached. The limited penetration speed of the dialysis membrane
was most likely the reason why few hours were needed to remove the free floating
dye from the solution.
To test the dialysis membrane’s penetration ability, dialysis bag was filled
with deionized water and 2 mg of Rhodamine B was loaded in to it. Only trace
amount of the dye were left in this sample after just 2 water changes (4 hours of
dialysis). Based on this result the observed release rate of the poloxamer modified
nanoparticles after 8 hours of the dialysis was considered to be true release rate
from the nanoparticles, rather than a combination of the last with the free dye
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Figure 5.5: Release rate, measured in grams of dye from gram of the cores, of the Rhodamine
B. Majority of the vesicles with poloxamer shell showed very similar release patterns at room tem-
perature which was relatively high at the beginning and leveled out after 8 hours. The lowest GD
sample showed a slower initial release but at the same time it did not loose as much of the release
rate with time and maintained relatively linear release from the beginning. Unmodified particles
worked mostly as a grab and hold vesicle showing very limited release with time.
leakage from the membrane. The rate of the release before the 8th hour is most
likely a combination of the two. The burst release test was done on the same
samples at the 10th hours of the experiment eliminate the possibility of the sample
preparation procedure influencing the observed results. After heating for 2 hours
samples were again cooled to room temperature, supernatant was removed and
fresh water was added to the samples. The rest of the room temperature release
rate measurements were done on the same samples at the indicated time intervals.
To check the influence of the equilibrium states on the release efficiency of
the different grafting densities samples were left in the same dialysate water for
17 hours. As expected the release rate has dropped to almost zero due to small
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dye concentration gradient between the dialysate water and the sample. After the
dialysate water was replaced with fresh deionized water the release efficiency was
restored and remained fairly constant for the next 10 hours. This results suggest
that the device will maintain its performance upon storage. Equilibrium concentra-
tion of the dye will be reached within the first few hours after the dilution and the
majority of the dye (or drug) content will still be encapsulated in the shell of the
nanoparticles until the injection or replacement of the storage water.
5.3 Conclusion.
Core shell system capable to retain and release upon request small molecules
was developed. Proposed system combines simple synthesis with high stability of
the device, while maintaining its bio-compatibility. The ability to choose multi-
ple commercially available poloxamers is expected to allow us the possibility to
program the temperature of the burst release of the drug. Described here in is a
technique that allows to prepare a well defined device with the desired properties
simply through the control over the grafting density of the poloxamer on the propar-
gyl acrylate core. Device can be programmed to serve either an extended release
purpose or to be used as a targeted drug delivery with a burst release of the drug
at the point of interest using temperature as a trigger. Possibility to create a device
with a well defined drug release profile opens a window of opportunity to increase
the treatment efficiency and decrease the number of side effect occurrences along
with their severity. The ability to program the device to burst release upon temper-
ature trigger combined with the possibility to manufacture cores in a wide range
of core sizes allows usto use this system as a targeted and temperature activated
cancer drug delivery device.
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5.4 Experimental methods
5.4.1 Materials and Reagents
All reagents were purchased from Sigma-Aldrich with at least 97% purity
level, solvents were purified using standard procedures.
5.4.2 Characterization
1H spectra were recorded on JEOL ECX-300 spectrometers (300MHz for
proton). Chemical shifts for protons are reported in parts per million downfield
from tetramethylsilane and are referenced to the carbon resonances of the solvent
(CDCl3: δ 7.26 or DMSO-d6: δ 2.50). Nanoparticles size was checked using Coulter
N4Plus DLS using 10 mm plastic cuvette. FTIR was done on a Nickolet Magna IR
6700 spectrometer equipped with diamond attenuated total reflectance accessory.
5.4.3 Nanoparticle preparation
Emulsion polymerization was performed in a single necked round bottom
flask (250 mL) equipped with the magnetic stirrer. Potassium persulfate (110 mg)
was dissolved in water (80 mL) and nitrogen was purged through the solution
for 15 minutes. Sodium dodecyl sulfate (90 mg) was added to the flask under
nitrogen purge. Obtained solution was stirred and placed in the preheated bath
at 75 ◦C for 3 minutes, then degassed solution of propargyl acrylate (4 mL) and
divinylbenzene (0.65 mL) were added to the main reaction flask. The mixture was
stirred at 75 ◦C under nitrogen purge for 90 minutes. The emulsion was allowed to
cool on air. Then mixture was filtered through paper filter. After filtering samples
were purified by dialysis using Spectra/Por Dialysis membrane with MWCO 50000.
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Dialysis was performed for 3 days at 40 ◦C in 18.2 Megaohms water with regular
water changes, typically every 8 hours. Nanoparticles were characterized using
DLS,SEM and BET analysis to determine average size and aggregation. Average size
of the nanoparticles, based on the analysis from all three techniques, was assumed
to be 28 nm. Obtained emulsion contained 45 mg/mL of nanoparticles.
5.4.4 Poloxamer modification
MeSO2-pluronic-L64. Pluronic-L64 (3.14 g, 1.064 mmol) was dissolved in dry
dichloromethane (DCM) (10 mL), triethylamine (0.132 g, 1.3 mmol) was added to
the solution. The obtained solution was stirred at room temperature, and methane-
sulfonyl chloride (48 mg, 0.42 mmol) was added drop-wise. The mixture was
stirred for 6 hours at room temperature; then was washed with water. The organic
layer was separated, dried with Na2SO4, filtered and evaporated under reduced
pressure. Yield 3.1 g (95%), clear oil. This product was used in the next step with-
out further purification. 1H NMR (CDCl3) δ 1.11 (m, 96H), 3.06 (s, 3H), 3.38 (m,
32H), 3.52 (m, 64H), 3.63 (m, 98H).
Pluronic-L64-N3. Sodium azide (195 mg, 3 mmol) was added into solution
of MeSO2-pluronic-L64 (3.1 g, 1.03 mmol) in dimethylformamide (DMF) (10 mL).
The mixture was stirred and heated to 80 ◦C for 3 hours. After cooling the mix-
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ture was extracted with DCM and washed with water 2 times. The organic layer
was separated, dried with Na2SO4, filtered and evaporated under reduced pressure.
Yield 2.27 g (75%), clear oil. Pluronic-L64-N3 was used in the next step without
further purification. 1H NMR (CDCl3) δ 1.07 (m, 96H), 3.34 (m, 32H), 3.48 (m,
64H), 3.59 (m, 98H).
5.4.5 Nanoparticle modification
Nanoparticle modification was performed using the azide alkyne Huisgen
cycloaddition reaction also known as Click chemistry. Typical procedure was used
as described elsewhere [41]. Copper(II) sulfate (CuSO4) (2 mg, 8 µmol) was added
to the propargyl acrylate nanoparticles suspension in water (2 mL) and stirred until
completely dissolved. Then solution of pluronic-L64-N3 (6) (22 mg, 7 µmol) in
water (2 mL) was added. Next the solution of CuSO4 (2 mg, 8 µmol) in water (2
mL) was added. The reaction was stirred and purged with nitrogen for 5 minutes,
then sodium ascorbate (10 mg, 50.5 µmol) was added. The reaction continued
at 28◦C for 24 hours under nitrogen purge. Reaction mixture was centrifuged at
10000G for 10 minutes. Separated nanoparticles were washed with the mixture
of water:Methanol 1:1 (20 mL). Then 1 mL of 0.1 M ethylenediaminetetraacetic
acid (EDTA) solution was added to remove copper catalyst. Nanoparticles were re-
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dispersed in 40 mL of 18.2 Megaohms water and sonicated for 3 minutes. After
sonication suspension was centrifuged at 10000G for 10 minutes. This step was
repeated 2 times. Next 0.1 mL of 20% sodium dodecyl sulfate (SDS) solution was
added to remove any unreacted poloxamer. Nanoparticles were re-dispersed in
40 mL of 18.2 Megaohms water and sonicated for 3 minutes. After sonication
suspension was centrifuged at 10000G for 10 minutes. This step was also repeated
twice. Lastly nanoparticles were re-dispersed in 40 mL of 18.2 Megaohms water and
sonicated for 3 minutes. After sonication suspension was centrifuged at 10000G for
10 minutes. This step was repeated 5 times to ensure that all impurities were
removed. After last centrifugation nanoparticles were redispersed in 10 mL of 18.2
Megaohms water and stored in the refrigerator.
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Chapter 6
Temperature triggered release of
vancomycin
Vancomycin is a potent antibacterial drug that suffers from poor bioavailabil-
ity due to poor water solubility and relatively high molecular weight thus limiting
its application for the bacteria induced diseases. In this study propargyl acrylate
- poloxamer nanocomposite (PAPN) ability to encapsulate and release when trig-
gered various molecules is used to promote the bioavailability of the vancomycin.
PAPN was prepared using emulsion polymerization of propargyl acrylate followed
by surface decoration with the poloxamer to a precisely controlled grafting den-
sity level. Activity of the PAPN loaded with vancomycin was compared to the free
drug and unmodified propargyl acrylate nanoparticles. Tests revealed comparable
activity of PAPN loaded with vancomycin to the freshly prepared free floating van-
comycin. Additionally, PAPN proved to be able to effectively encapsulate, deactivate
and preserve the vancomycin until the device was heated above lower critical solu-
tion temperature (LCST) of the poloxamer used. At the temperatures above LCST
PAPN was able to release vancomycin with the restoration of the vancomycin activ-
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ity even after one month of storage in solution, while comparable concentration of
free vancomycin became less potent against bacteria.
6.1 Introduction
Controlled release of biologically active molecules is superior to a simple
injection of a drug solution because it allows us to regulate the concentration of
the active components throughout the body, limiting the side effects probability
and at the same time increasing the treatment efficiency [151, 152, 153, 154].
Controlled release allows researchers to achieve high concentration of the drugs
at the site of interest while maintaining a safe level of the drug at other organs
and systems of the body[155, 156]. One of the mechanisms used to achieve the
controlled drug delivery is through the absorption-resorption of the drug into the
active layer of the carrier[157, 158, 159]. Vancomycin can significantly benefit
from the controlled drug delivery system due to its high activity towards multitude
of gram positive bacteria but low stability in aqueous solutions[160, 161]. Vari-
ous systems have been developed that are capable to encapsulate and then release
vancomycin[157, 162, 163, 164, 165] but all of these approaches suffer either from
the complex synthesis mechanisms, making the final price of the device too expen-
sive for the real world applications, or the proposed systems lack in the control
over the release patterns, placing strict limitations over the application conditions,
making the system useful only for a narrow range of patients.
Described herein is a drug delivery device build around bio-compatible propar-
gyl acrylate (PA) nanoparticle that was modified with poloxamer block copolymer
to achieve temperature triggered drug release. PA core was shown to be a versatile
build platform for the medical application [141, 40, 148]. Alkyne groups, that cover
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the surface of the PA nanoparticle, serve as an anchoring points to attach various
active molecules using azide alkyne cycloaddition reaction, also known as a Click
reaction. Click reaction offers the ability to permanently combine two molecules
under mild conditions with very high selectivity[166, 41], making Click reaction
the tool of choice when biologically active molecules are involved. Mild conditions
during Click reaction allows us to preserve the high biological activity of the drugs
or other active molecules during synthesis steps.
Poloxamer group of copolymers is a big commercial market of surfactants
and in recent years poloxamers have been demonstrated to be a potent respon-
sive polymer for medical applications due to their ability to stabilize various active
molecules in the aqueous environment[96, 98]. Poloxamers are known to form
pockets that can encapsulate biologically active molecules and dimensions of these
pockets are dependent on the temperature[30, 134] allowing us to use tempera-
ture differential as a trigger for the drug release mechanism. Poloxamer family of
copolymers offers the ability to fine tune the temperature of the drug release simply
through the selection of a correct ratio of the blocks in the copolymer[31, 34], mak-
ing it possible to use the increase in the temperature at the source of inflammation
as a trigger for the drug release, making targeted delivery a possibility. Decoration
of PA cores with poloxamer creates an active layer on the surface of PA nanoparticle.
This active layer can encapsulate drugs at the temperatures below lower critical so-
lution temperature (LCST) of the poloxamer and when exposed to the temperature
above LCST of the poloxamer the shell collapses, triggering the release of the drug.
Vancomycin is a glycopeptide antibiotic which is active towards multiple
Gram positive bacteria, including Escherichia coli and Staphylococcus aureus, and
is effective in the treatment of various bacterial diseases[167, 168]. This antibi-
otic has limited water solubility and it looses its biological activity relatively quickly
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when stored as a solution, because of these two factors vancomycin has a limited
range of applications and can benefit greatly when incorporated into the drug de-
livery device that can protect it from the environment and release it when required.
Most bacteria induced diseases cause inflammation at the cite of contamination,
this leads to a local increase in temperature by 2 or even 3 degrees. Based on the
previous results it is expected that this difference should be sufficiently big to trig-
ger the poloxamer collapse and thus initiating the release of vancomycin at the site
of inflammation, preventing the bacteria from spreading, while maintaining low
concentration of the drug in the rest of the body.
6.2 Results and Discussion
6.2.1 Characterization of propargyl acrylate poloxamer nanocom-
posite
Grafting density of the poloxamer on the propargyl acrylate (PA) core was
determined using Fourier transform infrared spectroscopy (FTIR) as described in
Chapter 4. For a set of samples with known ratios of the poloxamer to PA FTIR
spectra were collected. Poloxamer has a strong peak around 1100 cm−1 and PA
has a strong peak at 1150 cm−1, based on the ratio of this two peak a calibration
curve based on a known mass ratio of the poloxamer to PA was obtained. Using this
calibration curve poloxamer content in PAPN was determined. Figure 6.1 shows
FTIR spectra of unmodified PA nanoparticles, poloxamer and PAPN with poloxamer
content of 21 mass %. Experimentally precision of less than 1 mass % of poloxamer
in the mixture was confirmed.
Based on the measured core size, grafting density of the poloxamer was de-
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Figure 6.1: FTIR spectra of poloxamer (blue), PA particles (green) and mixture of the two (red)
showing good separation of the peaks for poloxamer (1100 cm−1) and PA particles (1150 cm−1).
Different grafting densities of poloxamer in PAPN can be distinguished through the ratio of these
two peaks.
termined to be 0.29 poloxamer chains per nm2 of PA core surface. As was shown
in Chapter 5 this grafting density is close to the optimal grafting density for small
molecule burst release, thus high temperature triggered release rate of the van-
comycin is expected. Figure 6.2 schematically shows proposed positioning of the
vancomycin inside of the poloxamer shell of the PAPN. Higher grafting densities of
the poloxamer would lead to a decrease in the encapsulation capacity, while lower
grafting density would limit the release rate at the elevated temperature, thus lim-
iting the effectiveness of the system for intended use. To better match the tem-
perature regime of the bacteria cells Pluronic-L62 version of poloxamer was used.
This copolymer has LCST of 24 ◦C which allowed us to use 18 ◦C and 36 ◦C as the
test temperatures. At this temperatures bacteria cells are not expected to be dam-
aged from the temperature induced effects, thus observed results would indicate
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influence of the device on the bacteria rather than temperature.
Figure 6.2: Left nanoparticle temperature is below LCST of the poloxamer, the shell is expanded
and can encapsulate vancomycin. Right image nanoparticle temperature is above LCST of the polox-
amer, the shell is collapsed, vancomycin is released from the shell. Image created by Olga Reukova
using 3DMax software package. Dimensions of the coils on the cartoon where scaled to represent the
theoretically calculated dimensions of particle and poloxamer blocks, vancomycin was not drawn to
the scale for clarity.
6.2.2 Binding yield of vancomycin
Experimentally it was determined that saturation of the poloxamer shell on
PAPN with vancomycin was achieved around 0.5 vancomycin molecules per nm2 of
the PAPN surface. To determine encapsulation efficiency excess of vancomycin (5
mg of vancomycin per 15 mg of cores, equivalent of 0.74 vancomycin molecules
per nm2) was added to PAPN solution at 18 ◦C , temperature below LCST of the
poloxamer used. The mixture was kept at 18 ◦C for 24 hours to allow ample time
for the vancomycin to penetrate into the shell and to reach the equilibrium state.
After 24 hours mixture was centrifuged at 6000G for 40 minutes, maintaining the
temperature at 7 ◦C . Vancomycin content in the supernatant was calculated based
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on the molar extinction coefficient of the vancomycin and the total volume of su-
pernatant that was collected, using same methodology as in Chapter 5. Then PAPN
was re-dispersed in cooled to 5 ◦C deionized water and centrifuged again at 6000G
for 40 minutes, while maintaining the temperature at 7 ◦C .
Vancomycin molar extinction coefficient was found using the same proce-
dure as in Chapter 5 for Rhodamine. A series of vancomycin dilutions with known
vancomycin concentration was prepared and UV/Vis absorbance for these samples
was measured. Attempt to measure vancomycin directly on the surface of PAPN re-
sulted in a typical scattering spectra and even through the solvent index matching
procedure the scattering was dominant, no reliable measurement of vancomycin on
the nanoparticles absorbance was possible.
To index match samples were dispersed in glycerin (solvent with the closest
refractive index value to the polymer) and UV/Vis spectra were collected resulting
in a typical scattering curve at the wavelength range of 300 nm and below, com-
pletely masking the vancomycin peak. Figure 6.3 shows absorbance of standard
solutions that were prepared and a typical scattering curve that was observed when
direct measurement of vancomycin on the nanoparticles was attempted.
As can be seen from the supernatant line, blue line of Figure 6.3, once the
nanoparticles were removed from the suspension remaining vancomycin was de-
tected making it possible to quantify the encapsulation efficiency. To ensure com-
plete PAPN removal from the supernatant solution, samples were filtered through
0.2 µm filter after centrifugation. Using the peak maximum for all of the standard
solutions of the vancomycin calibration curve was created, shown on Figure 6.4.
All unknown samples were compared to this curve to estimate the vancomycin con-
tent in them. Based on the absorbance data for each supernatant solution the total
amount of the vancomycin, that was not encapsulated by the nanoparticles or PAPN,
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Figure 6.3: Absorbance of standard Vancomycin solutions, from supernatant after modified
nanoparticles were removed from the suspension and from unmodified nanoparticles with van-
comycin.
was calculated. This number was subtracted from the loading amount and encapsu-
lation efficiency was calculated as the total amount of dye encapsulated divided by
the total surface area of the particles in the sample. Unmodified nanoparticles en-
capsulated 0.3 mg of vancomycin per mg of dry cores or 0.67 vancomycin molecules
per nm2 of the core surface, PAPN encapsulated 0.17 mg of vancomycin per mg of
dry cores or 0.38 vancomycin molecules per nm2 of the core surface.
6.2.3 Antibacterial activity on Escherichia coli
The efficiency of the temperature triggered release of the vancomycin from
PAPN was compared to the unmodified nanoparticles and to the free floating van-
comycin. PAPN without drug was used as a control of the PAPN toxicity. Efficiency
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Figure 6.4: Dependence of maximum absorbance for standard vancomycin solutions on the con-
centration of vancomycin in solution. Line represents linear curve fit, dots actual recorded data for
known concentrations.
of PAPN was tested on Escherichia coli and Staphylococcus aureus bacteria. For Es-
cherichia coli experiment bacteria was incubated in the fresh media for 24 hours
prior to being exposed to the PAPN and other control samples. Starting bacte-
ria suspension, as obtained after 24 hours of growing in media, was diluted 5E-6
times. For Staphylococcus aureus bacteria was incubated for 17 hours and diluted to
1.5E-5.
To each vial containing 5 mL of bacteria suspension equivalent of 1.4 mg of
dry cores was added. Phosphate-buffered saline (PBS) solution was used to protect
bacteria cells from bursting due to osmotic pressure and to remove all sources of
food for bacteria. This was done to maintain a stable number of live cells in each
sample. Bacteria that was left in the growing media would have a chance to grow,
thus the number of live cells in the sample would be growing over the course of
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the experiment, invalidating the results. For the control sample that contained
just vancomycin, 0.25 mg of vancomycin was added to 6 mL of PBS solution, this
amount is roughly equivalent to the total amount of the vancomycin that was added
with the PAPN sample according to the UV/Vis based calculations (1.4 mg of core *
0.17 mg/mg encapsulation efficiency = 0.238 mg).
Samples were separated into two groups and incubated for 24 hours at 18 ◦C
or 36 ◦C, above and below LCST of the poloxamer used. After incubation 0.1 mL of
each sample was seeded on 150 mm Petri dish with the growing agar and bacteria
was allowed to grow at the optimal temperature and humidity environment (36
◦C and 100% humidity) until a distinct colonies were observed on the surface of
agar media. Typical time required was between 24 and 48 hours. Each sample
was prepared in triplicates. Number of the colonies per Petri dish for each sample
was counted and normalized according to the number of the colonies in the control
sample, sample that was not treated with anything, results are shown on Figure 6.5.
As can be seen from the Figure 6.5 0GD+vancomycin bar - unmodified nanopar-
ticles loaded with vancomycin had a very limited effectiveness in killing the bacteria
at either temperature. PAPN that did not have any vancomycin in it, 0.29GD bar on
Figure 6.5, showed just slight toxicity towards the bacteria, which was also mostly
independent from the temperature. This result also suggests that the device itself
is safe enough and is not the main factor influencing the death of the bacteria.
PAPN loaded with vancomycin, 0.29GD+vancomycin bar on Figure 6.5, showed a
slight increase in the number of colonies at 18◦C and had the same effectiveness as
the free floating vancomycin at 36◦C. Very high survivability of the bacteria in the
presence of the PAPN loaded with vancomycin is indicative of the PAPN ability to
deactivate the drug while the drug is encapsulated in the poloxamer shell. Similar
effectiveness of the PAPN to the free floating vancomycin at the elevated temper-
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Figure 6.5: Number of colonies that has grown on petri dish after E. coli bacteria was exposed
to PA particles with vancomycin, PAPN, PAPN with vancomycin, pure vancomycin and control in
phosphate-buffered saline (PBS) solution. Top graph bacteria was incubated at 18C◦C, bottom graph
- at 36◦C.
atures suggests that vancomycin was released from the shell and its antibacterial
activity was restored, indicating that proposed system have completed its designed
task: drug was encapsulate, protected and then release in a controlled manner,
restoring its bio-activity.
As can be seen from the normalization of the observed number of colonies
as shown on Figure 6.6. PAPN loaded with vancomycin had superior performance
compared to a free floating vancomycin. PAPN loaded with vancomycin was much
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more efficient in controlling the population of the bacteria compared to the unmod-
ified propargyl acrylate nanoparticles, showing the importance of the temperature
triggered mechanism introduced with the addition of the poloxamer at a correct
grafting density.
Figure 6.6: Normalized number of the colonies that survived at 36 ◦C compared to 18 ◦C . Control
sample is the Escherichia coli bacteria that was not treated with anything and was just diluted with
PBS to match bacteria concentration of other samples. The rest of the samples were normalized
against the Control sample.
As a possible mechanism of the enhanced PAPN efficiency compared to the
pure vancomycin a limited water solubility of the last is proposed. PAPN being
decorated with the ethylene oxide groups on the outside has a much batter wa-
ter compatibility thus upon heating it, facilitates a much better spreading of the
vancomycin through the solution volume, enhancing vancomycin effectiveness.
The increase in the number of colonies that survived in the presence of PAPN
loaded with vancomycin (Figure 6.5) demonstrates the effectiveness of the designed
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system in the shielding of the drug from the environment and the shielding of the
environment from the drug at temperatures below LCST. This technology has a
potency to be used for both bacterial diseases and cancer treatment since it allows
to deliver high concentration of active molecules to the target regions and release
these molecules in the areas where there is an inflammation or actively growing
tissue, resulting in the local increase in the temperature.
6.2.4 Antibacterial activity on Staphylococcus aureus
Escherichia coli is a good and safe test subject to work with, but for the med-
ical application much more valuable is the data showing device efficiency against
more aggressive bacteria. Staphylococcus aureus is often used as a test bacteria
due to insufficient efficiency of the currently available methods of treatment for
the patients that have been infected by this bacteria and due to the severe com-
plications that can be caused by this bacteria. Staphylococcus aurues treatment is
often challenging and require high doses of antibiotics thus systems that can en-
hance antibiotic activity are in high demand. Working with Staphylococcus aureus
requires special care from the researcher to prevent self-contamination and to avoid
release of the bacteria into the environment, that is why initial study was done on
Escherichia coli bacteria.
Experiment protocol for Staphylococcus aureus was the same as for Escherichia
coli. First bacteria was incubated in fresh media to obtain a colony at the optimal
growth phase. Experimentally time needed to reach log growth phase was 18 hours
at 36 ◦C compared to 24 hours for Escherichia coli. The conclusion on the time re-
quired was made based on the number of cells that were able to survive in the PBS
for 6 hours. If the bacteria growth was stopped after the log growth phase the sur-
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vivability of the cells in the PBS solution was much lower than for the bacteria that
was taken at log growth phase, often leading to 80% or more of cell death during
bacteria storage in PBS at 36◦C for 6 hours. The bacteria that was taken at optimal
growth phase showed only 20 to 30% cell death under the same conditions.
Staphylococcus aureus suspension was treated with freshly prepared solu-
tions of unmodified nanoparticles with vancomycin, PAPN with vancomycin, PAPN
control, and 1 month old solutions of vancomycin and PAPN with vancomycin, us-
ing the same methodology as for the Escherichia coli bacteria experiment. After 6
hours of incubation 0.1 mL of each sample was seeded onto agar media in 150 mm
Petri dishes. Petri dishes were stored in controlled environment incubator at opti-
mal temperature and humidity for bacteria, 100% humidity and 34◦C temperature,
until colonies were big enough to be clearly visible by eye. Pictures of each Petri
dish were taken using 16 Megapixel Samsung camera over a black background.
This pictures were magnified using Microsoft paint software package and number
of colonies in each picture was counted. Control sample, bacteria in PBS, was used
as a normalization sample and number of colonies for the rest samples were nor-
malized using this number, results are shown on Figure 6.7.
As can be seen from Figure 6.7 pure vancomycin looses part of it’s activ-
ity towards bacteria during storage, while vancomycin that was encapsulated in
PAPN has almost the same activity after 1 month of storage in solution, both sam-
ples are not significantly different from control at 18 ◦C temperature, while both
32 ◦C temperature samples killed all bacteria, same result as for freshly prepared
vancomycin. We suspect that this protection is a result of poloxamer shielding ef-
fect. Vancomycin in solution can be oxidized by diluted oxygen or hydroxyl groups
present in water. Vancomycin that is encapsulated inside of the poloxamer shell is
less accessible for oxygen or hydroxyl groups since it is surrounded by poloxamer
124
NS NS
NS
Figure 6.7: Number of the colonies that survived at 36 ◦Ccompared to 18 ◦C. Control sample is
the Staphylococcus aureus bacteria that was not treated with anything and was just diluted with PBS
to match bacteria concentration of other samples. ”S” indicates statistically significant difference
from the control sample, ”NS” indicates no statistically significant difference from control according
to ANOVA calculator.
chains rather than water molecules. Poloxamer vancomycin interaction is thermo-
dynamically preferred thus other molecules has to compete with poloxamer chains
to get close enough to vancomycin to cause damage, thus decreasing the probability
of unwanted reactions that lead to destruction of vancomycin.
For Staphylococcus aureus similar to Escherichia coli patterns of bacteria growth
were observed. As can be seen from the Figure 6.7 unmodified nanoparticles loaded
with vancomycin showed some activity towards bacteria cells, but there is not
enough temperature dependence for this device to make it a valuable candidate
for controlled drug delivery application. More importantly vancomycin is active at
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both temperatures proving that there is no control over the drug release for this sim-
plest case, supporting the need to decorate nanoparticle surface with the poloxamer
copolymer.
PAPN without vancomycin showed almost no influence on the bacteria sur-
vivability at low temperatures, not significantly different results from the control,
but there was some statistical decrease in the number of cells that survived at tem-
perature above LCST. We do not have an exact reason why this is happening, and
as some of the possible reasons for this toxicity we propose effect of the loading
amount of nanoparticles: at 0.233 mg/ml particle density is relatively high and
can be above the toxic threshold; additionally these nanoparticles were purified 5
times in centrifuge with 1 EDTA run followed with 2 ligand exchange repetitions
(ca. Chapter 4) leaving a possibility that some copper ions orother toxins were still
absorbed on the PAPN. Upon statistical analysis of PAPN and PAPN with vancomycin
results it was found that observed results are statistically significant and observed
efficiency of PAPN with vancomycin is significantly more effective and indicates that
the vancomycin was in fact released from the PAPN shell and bacteria was effected
by this released vancomycin rather than PAPN itself.
Statistical significance calculations were performed using online One-Way
analysis of variance using ANOVA Calculator (http://www.socscistatistics.com/tests/
anova/default2.aspx). Sample variance was compered to a control sample for each
group of sample at two temperatures. For the 18 ◦C set of samples the following
parameters were calculated: the f-ratio value for fresh vancomycin is 1036.84, the
p-value is < 0.00001 (significant at p < .01); the f-ratio value for 1 month old van-
comycin is 18.93, the p-value is 0.0121 (significant at p < .01); the f-ratio value for
PA particles with vancomycin is 259.02, the p-value is 0.000087 (significant at p <
.01); the f-ratio value for PAPN is 0.358, the p-value is 0.58 (insignificant at p <
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.01); the f-ratio value for fresh PAPN+vancomycin is 13.49, the p-value is 0.0349
(insignificant at p < .01); the f-ratio value for old PAPN+vancomycin is 11.58, the
p-value is 0.0424 (insignificant at p < .01). For the 36 ◦C set of samples the follow-
ing parameters were calculated: the f-ratio value for fresh vancomycin is 1036.84,
the p-value is < 0.00001 (significant at p < .01); the f-ratio value for old van-
comycin is 575.24, the p-value is 0.000018 (significant at p < .01); the f-ratio value
for PA particles with vancomycin is 206.87, the p-value is 0.000136 (significant at
p < .01); the f-ratio value for PAPN is 179.34, the p-value is 0.00018 (significant
at p < .01); the f-ratio value for fresh PAPN+vancomycin is 1036.84, the p-value is
< 0.00001 (significant at p < .01); the f-ratio value for old PAPN+vancomycin is
1036.84, the p-value is < 0.00001 (significant at p < .01).
6.3 Conclusion
The bio-availability of the vancomycin was improved through the use of
the propargyl-acrylate poloxamer nanocomposite. Vancomycin was encapsulated
in to the PAPN and remained inactive at room temperature, allowing the bacteria
to grow. Poloxamer ability to change the size and shape of its coils was used to
achieve a controlled release of the vancomycin at the temperature above LCST of
the copolymer used. Besides being able to encapsulate and release the vancomycin
upon heating, PAPN proved to be effective in protecting it’s cargo from the envi-
ronment deactivating the drug until the system is triggered with the temperature.
PAPN offers a distinct advantage over the direct injection of the vancomycin since
it allows to control the moment when the drug is activated.
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6.4 Materials and Methods
6.4.1 Materials and Reagents
All reagents were purchased from Sigma-Aldrich with at least 97% purity
level, solvents were purified using standard procedures.
6.4.2 Characterization
1H spectra were recorded on JEOL ECX-300 spectrometers (300MHz for
proton). Chemical shifts for protons are reported in parts per million downfield
from tetramethylsilane and are referenced to the carbon resonances of the solvent
(CDCl3: δ 7.26 or DMSO-d6: δ 2.50). Nanoparticle size was checked using Coulter
N4Plus DLS using 10 mm plastic cuvette. UV/vis spectra was obtained using Perkin
Elmer Lambda 850 spectrometer. Scanning electron microscopy was performed on
a Hitachi S4800 FESEM at maximum accelerating voltage of 20.0 kV, images were
analyzed using Quartz PCI v.8.5 software package. FTIR was done on a Nickolet
Magna IR 6700 spectrometer equiped with diamond attenuated total reflectance
accessory.
6.4.3 Nanoparticles preparation
Emulsion polymerization was performed in a single necked round bottom
flask (250 mL equipped with the magnetic stirrer. Potassium persulfate (110 mg)
was dissolved in water (80 mL) and nitrogen was purged through the solution for
15 minutes. Sodium dodecyl sulfate (90 mg) was added to the flask under nitrogen
purge. Obtained solution was stirred and placed in the preheated bath at 75 ◦C for
3 minutes, then degassed solution of propargyl acrylate (4 mL) and divinylbenzene
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(0.65 mL) were added to the main reaction flask. The mixture was stirred at 75
◦C under nitrogen purge for 90 minutes. The emulsion was allowed to cool on air.
Then mixture was filtered through paper filter. After filtering samples were purified
by dialysis using Spectra/Por Dialysis membrane with MWCO 50000. Dialysis was
performed for 3 days at 40 ◦C in 18.2 Megaohms water with regular water changes,
typically every 8 hours. Nanoparticles were characterized using DLS analysis to
determine average size. Average size of the nanoparticles was found to be 28 nm.
Obtained emulsion contained 45 mg/mL of nanoparticles.
6.4.4 Poloxamer modification
MeSO2-pluronic-L62: Pluronic-L62 (3.14 g, 1.086 mmol) was dissolved in
dry dichloromethane (DCM) (10 mL), triethylamine (0.132 g, 1.3 mmol) was added
to the solution. Obtained solution was stirred at room temperature and methanesul-
fonyl chloride (48 mg, 0.42 mmol) was added drop-wise. The mixture was stirred
for 6 hours at room temperature, then was washed with water.The organic layer
was separated, dried with Na2SO4, filtered and evaporated under reduced pres-
sure. Yield 3.1 g (95%), clear oil. This product was used in the next step without
further purification. 1H NMR (CDCl3) δ 1.11 (m, 87H), 3.06 (s, 3H), 3.38 (m, 29H),
3.52 (m, 28H), 3.63 (m, 72H).
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Pluronic-L62-N3. Sodium azide (195 mg, 3 mmol) was added into solution
of MeSO2-pluronic-L62 (3.1 g, 1.03 mmol) in dimethylformamide (DMF) (10 mL).
Mixture was stirred and heated to 80 ◦C for 3 hours. After cooling the mixture was
extracted with DCM and washed with water 2 times. The organic layer was sep-
arated, dried with Na2SO4, filtered and evaporated under reduced pressure. Yield
2.27 g (75%), clear oil. Pluronic-L64-N3 was used in the next step without further
purification. 1H NMR (CDCl3) δ 1.07 (m, 87H), 3.34 (m, 29H), 3.48 (m, 59H), 3.59
(m, 72H).
6.4.5 Nanoparticles modification
Nanoparticle modification was performed using the azide alkyne Huisgen cy-
cloaddition reaction also known as Click chemistry. Typical procedure was used as
described elsewhere [41]. Copper(II) sulfate (CuSO4) (2 mg, 8 µmol) was added
to the propargyl acrylate nanoparticles suspension in water (2 mL) and stirred until
completely dissolved. Then solution of pluronic-L62-N3 (6) (40 mg, 16 µmol) in
water (2 mL) was added. Next the solution of CuSO4 (2 mg, 8 µmol) in water (2
mL) was added. The reaction was stirred and purged with nitrogen for 5 minutes,
then sodium ascorbate (10 mg, 50.5 µmol) was added. The reaction continued
at 28◦C for 24 hours under nitrogen purge. Reaction mixture was centrifuged at
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10000G for 10 minutes. Separated nanoparticles were washed with the mixture
of water:Methanol 1:1 (20 mL). Then 1 mL of 0.1 M ethylenediaminetetraacetic
acid (EDTA) solution was added to remove copper catalyst. Nanoparticles were re-
dispersed in 40 mL of 18.2 Megaohms water and sonicated for 3 minutes. After
sonication suspension was centrifuged at 10000G for 10 minutes. Next 0.1 mL of
20% sodium dodecyl sulfate (SDS) solution was added to remove any unreacted
poloxamer. Nanoparticles were re-dispersed in 40 mL of 18.2 Megaohms water and
sonicated for 3 minutes. After sonication suspension was centrifuged at 10000G
for 10 minutes. This step was repeated one more time. Lastly nanoparticles were
re-dispersed in 40 mL of 18.2 Megaohms water and sonicated for 3 minutes. After
sonication suspension was centrifuged at 10000G for 10 minutes. This step was re-
peated 3 times to ensure that all impurities were removed. After last centrifugation
nanoparticles were redispersed in 10 mL of 18.2 Megaohms water and stored in the
refrigerator.
6.4.6 Molar extinction coefficient of vancomycin
Molar extinction of vancomycin was calculated in DI-H2O to be 6.53 M−1cm−1
at 280 nm using multiple solutions of concentrations 0.5 mg/mL, 0.25 mg/mL,
0.125 mg/mL and 0.0625 mg/mL. Procedure was the similar to the Rhodamine B
procedure described in Chapter 5. For each concentration UV/Vis spectra was re-
coded and graph of absorbance maximum versus concentration was created. Molar
extinction coefficient was assumed to be equal to the slope of the line of this graph.
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6.4.7 Bacteria stock preparation and mixing
Bacteria was grown in the LB Broth for 24 hours at 37 ◦C Escherichia coli, and
17 hours at 34 ◦C for Staphylococcus aureus. After initial incubation period bacteria
was diluted in phosphate-buffered saline (PBS) solution to 1.5E-5 for Staphylococ-
cus aureus and 5E-6 for Escherichia coli of the original concentration. 0.1 mL of the
obtained solution was added to 5 mL of PBS in 15 mL centrifuge vial. Then nanopar-
ticle samples were added to this vial, amount of the solution of the nanoparticles
added was measured to contain 1.4 mg of dry cores equivalent, in case of free van-
comycin equivalent of 0.25 mg of dry drug was added. Next volume of each sample
was brought to a total of 6 mL using PBS. After this samples were left at 18 ◦C or
36 ◦C for 24 hours for Escherichia coli, or 6 hours for Staphylococcus aureus to allow
ample time for the drug to kill bacteria. After 24 hours 0.1 mL of each sample was
seeded on the Petri dish with LB agar. Bacteria was allowed to grow at optimal
conditions (36 ◦C and 100 % humidity) until colonies were easy to detect by the
naked eyes. Pictures of each Petri dish were taken and number of colonies per Petri
dish was recorded.
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Chapter 7
Concluding remarks
7.1 Summary
The objective of the presented work was to explore the possibility to use
propargyl acrylate poloxamer nanocomposite (PAPN) as a temperature responsive
device capable to encapsulate active molecules and perform various tasks ranging
from the enhanced medical imaging to the drug delivery.
Through the combination of the propargyl acrylate core with a defined amount
of the poloxamer nanocomposite of a well defined structure was synthesized. Easy
and quick methods to characterize the final assembly were developed. The required
tools along with the equations needed to determine the final composition of the
PAPN were designed and derived.
Through the inclusion of the two dyes that form a FRET pair into the nanocom-
posite structure a possible mechanism of the encapsulation and the release was
proposed. Poloxamer middle, PPO block, forms a favorable environment for the
small molecules that have aromatic rings in their structure and helps to stabilize
these molecules in the water based systems, human body being one of such sys-
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tems. Changes in the poloxamer coil packing with the temperature were proposed
as the main mechanism of PAPN response.
Control over the poloxamer grafting density(GD) allowed to manipulate the
encapsulation efficiency and the release rate of the active molecules. The impor-
tance of the precise control over the GD was demonstrated on the example of the
Rhodamine B dye.
The ability of the PAPN to encapsulate and release vancomycin was demon-
strated on the example of Escherichia coli and Staphylococcus aureus bacteria. PAPN
filled with vancomycin was successfully used to control the growth of the bacteria
with the temperature. The ability of PAPN to preserve bio-activity of the vancomycin
was discovered.
7.2 Recommendation for future research
Current work investigated only two of the multitude of the copolymers in the
poloxamer copolymer family. Selecting a different version of the poloxamer should
in theory yield a different range of the temperature response allowing researcher to
fine tune the system to a desired applications. Two poloxamers used in this work
had an LCST of 24 ◦C and 58 ◦C which is below and above the normal human
body temperature range. The most value for the medical application would have
a system with the poloxamer that has LCST of 37.5 ◦C, unfortunately there is no
commercially available version of the poloxamer currently available on the market
with 37.5 ◦C temperature of response. Poloxamer family of copolymers was exten-
sively studied over the past few decades and current synthetic techniques allow the
researcher to synthesize any copolymer composition. Available knowledge about
the dependence of the LCST temperature on the block length and ratio makes it
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possible to predict the correct structure of the poloxamer that is needed to achieve
LCST of 37.5 ◦C, though additional research is required in this direction.
Next phase for the project would involve testing of the PAPN on a cancer
cells eventually moving all the way to the human trials. Substitution of vancomycin
with doxorubicin or other anticancer drug would be required in order to test the
system for the anticancer activity.
Another area of possible application for the PAPN is in the waste water treat-
ment plants. PAPN’s ability to trap organic molecules and then release them upon
heating can be used to remove toxic waste from the water supply system and to
concentrate this waste for further processing. Since the poloxamer temperature in-
duced changes are reversible it is expected that system based on the PAPN can be
reused multiple times making it cost effective alternative to the currently available
filtration systems.
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Appendix A BET analysis
153
Appendix B Poloxamer modification two end proba-
bility table
Figure 1: Probability of one and two end modification with azide group for poloxamer as described
in Chapter 4, probability calculations are based on the loading ratio that was used for the reaction,
higher loading ratio would lead to a much higher probability of dual end modified poloxamer creat-
ing a high probability to crosslink multiple particles together.
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Appendix C NMR data
Figure 2: 1HNMR spectra of Pluronic L64 as received. δ 1.11 (32) CH3 groups from PPO block, δ
3.38 (32) CH groups in PPO block, δ 3.53 (32) CH2 groups from PPO block, δ 3.64 (48) CH2 groups
from both PEO blocks.
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Figure 3: 1HNMR spectra of Pluronic L64 as received. δ 1.07 (29) CH3 groups from PPO block, δ
3.33 (29) CH groups in PPO block, δ 3.47 (29) CH2 groups from PPO block, δ 3.57 (36) CH2 groups
from both PEO blocks.
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Figure 4: 1HNMR spectra of Pluronic L64 as received. δ 1.11 (32) CH3 groups from PPO block,
δ 3.06 (1) CH3 group from MeSO2 group, δ 3.38 (32) CH groups in PPO block, δ 3.52 (32) CH2
groups from PPO block, δ 3.62 (48) CH2 groups from both PEO blocks.
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Figure 5: 1HNMR spectra of Pluronic L64 as received. δ 1.06 (32) CH3 groups from PPO block, δ
3.33 (32) CH groups in PPO block, δ 3.47 (32) CH2 groups from PPO block, δ 3.57 (48) CH2 groups
from both PEO blocks.
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Figure 6: 1HNMR spectra of Pluronic L64 as received. δ 1.13 (32) CH3 groups from PPO block,
δ 3.07 (1) CH3 group from MeSO2 group, δ 3.38 (32) CH groups in PPO block, δ 3.54 (32) CH2
groups from PPO block, δ 3.63 (48) CH2 groups from both PEO blocks.
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Figure 7: 1HNMR spectra of Pluronic L64 as received. δ 1.11 (32) CH3 groups from PPO block, δ
3.38 (32) CH groups in PPO block, δ 3.52 (32) CH2 groups from PPO block, δ 3.62 (48) CH2 groups
from both PEO blocks, δ 1.40, 1.70, 1.86, 3.21, 7,14, 7.65, 8.38-8.64 Naphthalimide signals .
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